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Abstract 
The first step of cap-dependent translation is mediated by the mRNA cap-binding 
protein eukaryotic initiation factor 4E (eIF4E). Although involved in translating nearly all 
cellular transcripts, mRNAs vary widely in their translational response to eIF4E activity 
changes. Prior studies of mRNA structure revealed several features governing eIF4E 
responsiveness; however, most of this knowledge is based on comparison of two levels 
of eIF4E activity with unclear physiological relevance. To identify mRNA structural 
features that govern genome-wide ribosome recruitment across a full range of 
physiological eIF4E activities, we precisely modulated eIF4E activity using an eIF4E-
inducible system together with 4Ei-1, an inhibitor of the eIF4E-5’mRNA cap association. 
We identified genes that were more (4E hypersensitive) or less (4E hyposensitive) 
responsive to eIF4E activity changes than average. Distinct characteristics associated 
with each class: 4E hypersensitive genes had longer 5'UTRs with higher GC content, 
longer 3'UTRs with lower GC content; more AU-rich elements and a higher density of 
unique microRNA targets sites than typical genes. Importantly, these structural 
characteristics predicted the translational response across the dose range of 4Ei-1. Gene 
ontology analysis showed an association between 4E hypersensitive genes and 
proliferation; and cell cycle experiments with 4Ei-1 validated this result. A search for the 
outcome and mechanism of this proliferative gene activation in a physiological setting 
revealed that abrupt gain of eIF4E function in quiescent cells first triggers G0 exit and 
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then cell cycle transit at least partially by increasing ribosome recruitment to cyclins C 
and D1. Whereas cyclin C is not necessary for this effect; cyclin D1 is indispensable, 
although not sufficient. Our findings provide important insights into mRNA properties of 
eIF4E-modulated translational control. 
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Chapter 1 THESIS INTRODUCTION 
Multiple mechanisms regulate eukaryotic gene expression 
Eukaryotic gene expression is a multistep progression of transcription, translation, and 
eventual degradation of messenger RNAs and proteins. This progression is coordinated 
by several regulatory nodes arrayed in a series. Genomic, transcriptional, and 
posttranslational regulatory mechanisms are well established. However, it is now 
increasingly recognized that gene expression is also subject to translational control. 
Highlighting this trend, a recent comprehensive analysis of mammalian gene expression 
published in Nature concluded that “the cellular abundance of proteins is predominately 
controlled at the level of translation” (1). 
As with all other major cellular processes, this process of converting mRNA into protein 
is regulated at multiple stages. These include translation initiation, elongation, 
termination, and mRNA turnover/stability. This thesis provides important insights into 
the structural and functional mRNA properties of translation controlled at the level of 
initiation by eukaryotic initiation factor 4E (eIF4E). 
Cap-dependent translation 
In eukaryotes, translational occurs almost exclusively through two mechanisms termed 
cap-dependent and cap-independent translation, although some mRNAs blur these 
  2 
boundaries (2). Although a small subset of mRNAs can be translated in a cap-
independent method through direct contact of the translational machinery with their 
internal ribosome entry site (IRES), under most physiological conditions the vast 
majority of mRNAs are translated utilizing cap-dependent translation. The “cap” refers 
to the 5’ mRNA structure m7GpppN, where m7G is 7-methylguanosine and N is the first 
nucleotide of mRNA (3). This cap is crucial for the efficient translation of the majority of 
cellular mRNAs and is required for cap-dependent translation initiation (4). 
Translation initiation is a key regulatory hub 
Initiation of cap-dependent translation functions as a key regulatory hub in the gene 
expression pathway. Translation rates are modulated by a variety of environmental 
signals including growth factors, nutrient availability, and stress (5, 6). These 
modulations lead to outcomes ranging from apoptosis to cell cycle progression and cell 
growth (5, 7). Because of the profound effects that translation can have on cellular 
functions, translation is tightly controlled primarily at the level of initiation (8). 
eIF4E binds to the m7G 5’-cap of mRNA 
Availability of active eukaryotic initiation factor 4E (eIF4E) is believed to be rate limiting 
for cap-dependent translation (9). eIF4E is an evolutionary conserved 25kDa polypeptide 
which specifically recognizes and directly binds to the 5’ mRNA cap (10). The mechanism 
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of binding occurs either through a one or two step process, which seems to depend on 
temperature and the relative availability of eIF4E and cap (11, 12). In either model, the 
binding of the cap structure to eIF4E is the defining event in cap-dependent translation 
and therefore represents a target for pharmacological intervention in translational 
control (13, 14). 
eIF4E as discussed in this thesis is more preciously termed eIF4E1, and is the most 
characterized member of the eIF4E protein family. Other members include eIF4E1b, 
eIF4E2 (also known as 4EHP), and eIF4E3 (15). As these three eIF4E proteins exhibit as 
much as 200-fold weaker affinities for the mRNA cap; they are functionally distinct from 
eIF4E1 in gene regulation, oncogenic capacity, and binding partner specificity (16-18). 
Assembly and function of the eIF4F complex 
eIF4E1 (hereafter termed eIF4E or 4E), is a member of the heterotrimeric initiation 
complex eIF4F which also includes the scaffolding protein eIF4G and the RNA helicase 
eIF4A. The eIF4A component of the eIF4F complex functions to unwind secondary 
structures in the 5’ untranslated region (UTR) of mRNA to reveal the initiation codon 
and facilitate ribosome loading (19). Poly(A) binding protein (PABP) also interacts with 
the docking protein eIF4G and can mediate the formation of a “closed-loop” circular 
messenger ribonucleoprotein (mRNP) complex by linking the cap and the poly(A) tail, 
thereby stimulating translation by enhancing the recycling of ribosomes on the mRNA 
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(4, 20). A simplified model focusing on eIF4E/eIF4F activity is shown here (Figure 1-1 
from (21)), but a more complete overview of the current knowledge of cap-dependent 
translation initiation and translational control is reviewed in (22). Briefly, the eIF4G 
component of the eIF4F complex bridges the mRNA to the 40S ribosomal subunit 
through the eIF3 adapter complex, the largest scaffolding initiation factor which is 
composed of 13 subunits. At this stage the 40S subunit is also complexed with eIF3, 
eIF1A, eIF1, eIF2, and a loaded Met-tRNA to form the 48S complex. Once this complex is 
bound to mRNA, eIF4A unwinds mRNA secondary structure as the complex scans the 
5’UTR of the attached mRNA in the 5’ to 3’ direction until an initiation codon in the 
proper sequence context is encountered. When the initiation codon is recognized, eIF5 
and eIF5B promote the hydrolysis of eIF2-bound GTP, which results in the displacement 
of the initiation factors and allows the joining of a 60S ribosomal subunit. This changes 
the conformation of the attached ribosome, marks the end of translation initiation and 
the start of elongation, and allows protein synthesis to continue. 
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Figure 1-1 Cap-Dependent Translation Overview 
Shown is a simplistic model overview of cap-dependent translation. Note that PABP, which 
circularizes the mRNA by binding to the poly(A)-tail and the mRNA cap, is not shown. This figure 
has been reprinted with kind permission from the American Association for Cancer Research. 
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Cap-independent translation - IRES 
The most common form of cap-independent translation is mediated by an internal RNA 
structure called an internal ribosome entry site (IRES), which recruits the ribosome 
independent of both the cap and the eIF4F complex and allows translation to proceed 
(23). IRES-mediated translation is used by some viruses but also exists on ~100 
eukaryotic cellular mRNAs, functioning in times of stress or in development when cap-
dependent translation is minimized (24). Although there are recent reports linking IRES-
mediated translation with cancer (25-27), deregulation of cap-dependent translation 
has a more established role in cancer. 
Translational control is corrupted in cancer 
The regulation and control of translation factors is critical in cancer genesis and 
development. Aberrant eIF4E overexpression causes resistance to apoptosis (28), 
increased proliferation (29) and transformation (30-32) in multiple cell lines including 
NIH3T3 fibroblasts. Consistent with regulation of these key cancer hallmarks, increased 
eIF4E activity has been detected in a multitude of human malignancies including lung, 
breast, colon, bladder, prostate and gastrointestinal cancers; head and neck squamous 
cell carcinoma, fibrosis, lymphomas, leukemias and neuroblastomas, where high eIF4E 
activity correlates with disease progression and poor clinical outcome (33, 34). This 
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suggests that eIF4E functions as an oncogene by specifically modulating the translation 
of key proteins which are beneficial for the cancer phenotype. 
eIF4E selectively targets a subset of mRNAs 
Although eIF4E is necessary for efficient translation of almost all cellular mRNAs, 
changes in eIF4E activity in the physiological range only modestly affect the translation 
of most mRNAs (33) while having a major effect on a subset of mRNAs designated 4E-
sensitive (35). Initial studies characterized this subset as containing long, highly 
structured and complex 5′ UTRs with relatively high G+C base pair content (hereafter 
called GC content), rendering these transcripts strongly dependent on the unwinding 
activity of the eIF4A helicase (36), as genes with relatively long and structured 5’UTRs 
are translated less efficiently (37). This has been corroborated by several single-gene 
and mechanistic studies where long and highly structured 5’UTRs mediated 4E-sensitive 
translation. mRNAs with relatively long and structured 5′-UTRs which are sensitive to 
eIF4E include ornithine decarboxylase (38), ornithine aminotransferase (39), cyclin D1 
(40), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (41), ribonucleotide 
reductase (42), and vascular endothelial growth factor (VEGF) (43). These key 
translationally regulated genes are then capable of altering the cellular phenotype. 
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Regulation of eIF4E activity 
Due to the oncogenic capacity of eIF4E, its physiological activity is tightly regulated. The 
cells “eIF4E activity level” can be defined as the sum effect on translation initiation of 
eIF4E’s: total protein abundance, percentage of that eIF4E functionally available after 
accounting for regulatory binding to eIF4E regulatory proteins, phosphorylation state, 
and subcellular localization. 
4E-BPs and the mTOR pathway 
The activity of eIF4F is negatively regulated by the eIF4E-binding proteins (4E-BPs), a 
family of translation repressor proteins which compete with eIF4G for a common 
binding site on eIF4E (44) and thereby prevents formation of the eIF4F complex. The 4E-
BPs are themselves regulated by intracellular signaling including the mTOR pathway 
(45). The mTOR (mammalian target of rapamycin) kinase is the catalytic subunit of two 
molecular complexes: mTORC1 and mTORC2. The mTOR pathway regulates cell growth 
and division by simultaneously sensing energy, nutrients, and stress and is critically 
involved in tumorigenesis (Figure 1-2 from (46)).  mTORC1 indirectly regulates protein 
synthesis by phosphorylating the 4E-BPs leading to their release from eIF4E which is 
then free to form the eIF4F complex and initiate translation. mTORC1 and to a lesser 
extent mTORC2 can also be inhibited by the compound rapamycin (47, 48). 
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Figure 1-2 mTOR-regulated processes are involved in cancer. 
mTOR complex 1 (mTORC1) favors tumor genesis and maintenance of the cancer phenotype by 
driving the translation of oncogenes by relieving 4E-BP1-mediated inhibition of eIF4E via 
phosphorylation of the 4E-BPs, by inhibiting autophagy, by upregulating hypoxia-inducible factor 
1α (HIF1α) to increase angiogenesis, and by enhancing the accumulation of lipids by activating 
the transcription factor sterol regulatory element binding protein 1c (SREBP1c). mTORC2 also 
plays a part in tumorigenesis by activating Akt and other AGC family proteins, such as serum- 
and glucocorticoid-regulated kinase (SGK), thereby promoting cellular proliferation and survival. 
Furthermore, by promoting Akt-mediated glucose uptake and utilization, mTORC2 fuels the 
increased metabolism rate of cancer cells. This figure has been reprinted with kind permission 
from Nature Publishing Group. 
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c-Myc 
The c-myc (Myc) oncogene is the prototypical member of the Myc/Max/Mad 
transcription factor network, which regulates 15% of all genes and such divergent 
cellular functions such as protein biosynthesis, proliferation, apoptosis, differentiation, 
and energy metabolism (49). Myc can stimulate protein synthesis by up-regulating eIF4F 
activity (50). Up-regulation occurs as the transcription factor Myc regulates the total 
cellular abundance of all members of the eIF4F complex; eIF4E (51), eIF4A (52), and 
eIF4G (52). Together these proteins also exert an oncogenic effect as overexpression of 
eIF4E and Myc abolishes the apoptotic effect of Myc and pushes cellular proliferation 
(28, 32). In addition, eIF4E is able to increase Myc expression as Myc is also one of the 
first identified 4E-sensitve mRNAs (53), or a reduction of eIF4E expression decreases 
Myc expression (54). This data outlines a positive feed forward loop between increasing 
Myc and eIF4F expression and provides another potential molecular mechanism for the 
oncogenic capacity of Myc and eIF4E (55). 
Mnks 
eIF4E is also regulated by phosphorylation, although exactly how this effects function 
varies in normal and malignant tissue. Activation of the ERK and p38 MAP kinase 
pathways elicits phosphorylation of Mnk1, which is recruited by eIF4G, and then 
activated Mnk1 phosphorylates eIF4E at s209 (56, 57). Mnk2 constitutively 
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phosphorylates eIF4E and is not inducible under normal physiological conditions (58), 
although the mTOR inhibitor rapamycin may induce eIF4E phosphorylation through 
Mnk2a (59). Although eIF4E phosphorylation increases oncogenic transformation and 
mRNA transport (60), this phosphorylation is not required for cellular proliferation and 
translation under physiological conditions (61); thereby making the Mnks an attractive 
target for pharmacological intervention in cancer (62). Even though the direct effect of 
eIF4E phosphorylation on its cap binding affinity are still being debated (33), and it may 
play an in vivo role by suppressing the innate antiviral response (63); eIF4E 
phosphorylation does not appear to play a major role in the physiological regulation of 
translational control and development (62). 
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Summary 
Control of cap-dependent translation initiation is a critical hub for regulation of 
physiological cellular growth and is regularly usurped in cancer. This hub is principally 
regulated through the pleiotropic functions of the 5’ mRNA cap-binding protein eIF4E. 
eIF4E regulates cell growth on multiple levels and is believed to selectively 
translationally regulate a subset of mRNAs with long and highly structured 5’UTRs which 
are also critically involved in oncogenic functions. The regulation of eIF4E is complex and 
occurs on multiple levels: availability to form the eIF4F complex through inhibitory 
binding by the 4E-BPs and other regulatory proteins, protein abundance through a feed-
forward loop with Myc, and transformative capability through phosphorylation by the 
Mnks. Therefore the pharmacological targeting of specific eIF4E interactions allows 
targeting of eIF4E function at multiple levels, and the dose-dependent inhibition of a 
specific interaction allows a detailed exploration of that function of eIF4E. 
Rationale and purpose of study 
No previous studies have systematically examined translation genome-wide across the 
physiological range of eIF4E activity. Consequently, the aims of the study are as follows: 
(a) categorize genes based upon their translational requirement for eIF4E activity, (b) 
define the structural characteristics of 4E-sensitive genes, and (c) define a molecular 
mechanism for eIF4E-induced cell cycle progression. 
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Chapter 2 : Structural features of eIF4E hypersensitive 
mRNA translation are revealed by combining induction 
and chemical antagonism of eIF4E 
Introduction 
Translational control can be analyzed via microarray-polysomal 
analysis 
Pathological translational control manifests as a genome-wide reorganization of 
ribosome recruitment to mRNA and has been analyzed primarily in the context of 
established cancers. With the emergence of genome wide approaches to measure gene 
expression the hypothesis that long and highly structured 5’UTRs mediates pathological 
4E-sensitive translation was tested at a genome wide level. Early such studies used 
combined polysome-microarray analysis (64) to characterize the genome-wide effects of 
constitutively overexpressed eIF4E (65, 66), deleted 4E-BP1/2 (67), or induced 
overexpression of eIF4E (35). None of these studies directly identified a pattern where 
long 5’UTRs with high GC-content were enriched among genes showing 4E-sensitive 
translation. However, 4E-sensitive mRNAs did show a microRNA binding bias in their 
  14 
3’UTRs, and microRNAs are known to influence translation by direct inhibition of the 5’ 
cap recognition step (68). 
Limitations of previous systems 
Although prior studies characterized eIF4F sensitive genes in a variety of settings, the 
applicability of their results is restricted by scope. These studies were limited by 
potential indirect effects and counter regulation arising from long term culturing with 
constitutively active eIF4E (66) and/or by modulating eIF4E activity to a single high level 
which is outside the physiological expression range observed in rapidly proliferating cells 
(69). Another limitation of these studies is that all of them altered eIF4F activity using a 
single on/off intervention and did not precisely titrate eIF4E activity or alter its cap 
binding function. As a result these studies may have identified ample numbers of false 
positives among the 4E-sensitive genes which may have obscured the association with 
long and 5’ UTRs and high GC contents. More recently, two studies using the recent 
ribosome profiling technique to measure translation genome-wide completely 
challenged the role of the 5’UTR in 4F-sensitive translation when suggesting that 
inhibition of mTOR using chemical agents suppressed translation of a subset of genes 
with short 5’UTRs in a 4E-BP dependent manner (70, 71). These studies utilized a single 
dose of an mTOR inhibitor to depress hyperactivated translation in the context of 
prostate cancer and cultured cells in full growth media and did not analyze 3’UTR 
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characteristics. Furthermore, their 5’UTR observations may have been confounded by 
other mechanisms downstream of mTOR and as a result may not reflect 4E-sensitive 
translation. It was therefore important to complement this data by directly studying the 
effect on translation induced by differential eIF4E activity in the physiological range. 
Our system mimics physiological fluctuations in eIF4E activity 
We reasoned that a more measured approach could be required to understand the 
biological effects of dynamic changes in physiological eIF4E activity on 4E-sensitive 
translation. eIF4E abundance is tightly tuned to metabolic needs and fluctuates over the 
course of a cell cycle: scarce in quiescent cells, rising sharply in response to growth 
factors and peaking at the late G1 restriction point (69, 72). We therefore developed a 
model system allowing precise and rapid control of eIF4E activity within the 
physiological expression range by concurrently modulating eIF4E activity in quiescent 
cells using an inducible eIF4E protein expression system and the eIF4E inhibitor 4Ei-1. 
The stable, nontoxic tryptamine phosphoramidate prodrug 4Ei-1, which was used over a 
wide concentration range to allow studies of dose-dependent regulation, is activated 
intracellularly by histidine triad nucleotide binding protein 1 (HINT1). The resulting 
active compound 7-benzyl guanosine monophosphate (7-BnGMP) competitively and 
directly inhibits the association of eIF4E with the 5’-mRNA cap in a dose-dependent 
manner (73). Using this dual-mechanism system, we studied ribosome recruitment to 
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mRNA genome-wide as a function of eIF4E activity and identified structural 
characteristics of the 5’UTRs and 3’UTRs of 4E-sensitive transcripts. 
Summary 
We modulated eIF4E activity at two levels: total protein abundance and the percentage 
of that eIF4E available to bind the 5’mRNA cap after accounting for binding to the 
5’mRNA cap analogue 7-BnGMP. We identified genes that were more (4E 
hypersensitive) or less (4E hyposensitive) responsive to eIF4E activity changes than 
average. Here we show that structural characteristics of 4E hypersensitive (previously 
termed 4E-sensitive) transcripts (relative to typical genes) indeed include greater length 
and higher GC content of the 5’ UTR. In addition 4E-hypersensitive genes have longer 
3’UTRs with lower GC content and higher microRNA target site density. Moreover, in 
accordance with the established role of eIF4E activity in cell cycle progression, analysis 
of eIF4E hypersensitive mRNAs revealed enrichment for proliferation related genes and 
functional studies showed 4Ei-1 inhibited cell cycle transit in a dose-dependent manner. 
Thus 4E-sensitive translation depends on structural features of the 3’ and 5’ UTRs and 
does not associate with short 5’ UTRs. 
  
  17 
Results 
An in vitro model for precise modulation of eIF4E activity. 
To allow studies on how precisely tuned eIF4E activity impacts ribosome recruitment, 
we developed an inducible system in which expression of the rate limiting component of 
eIF4F, eIF4E, is induced with the progesterone antagonist mifepristone (MIF). To 
facilitate its detection, the induced eIF4E was tagged with hemagglutinin (HA-eIF4E). A 
2-fold increase in eIF4E approximates the maximum induction observed in rapidly 
proliferating cells (69), and a relevant model system should therefore show a similar 
dynamic range. We utilized quiescent cells that are contact inhibited and serum 
deprived as a model to minimize variations in eIF4E activity induced by fluctuations in 
intracellular signaling (e.g. caused by differences in confluence) (28). After screening a 
panel of clonal cell lines we selected one cell line (designated “4E-inducible”) as suitable 
for these studies as it showed no detectable baseline expression of ectopic HA-eIF4E 
while total eIF4E (endogenous + ectopic) was increased ~2-fold in response to low dose 
mifepristone (625 pM, to minimize off target effects) without downward compensation 
of endogenous eIF4E protein levels over the time period studied (Figure 2-1A). To 
account for mifepristone effects not related to eIF4E induction, another clonal cell line 
was selected for use as non-inducible control cells (designated “non-inducible”) as the 
cell line did not express HA-eIF4E after mifepristone treatment despite exhibiting the 
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antibiotic resistance of the GeneSwitch expression system plasmids (Figure 2-1A). 
Induction of the ectopic eIF4E gene in 4E-inducible cells was rapid, with a time 
dependent increase in HA-eIF4E mRNA apparent within 1h (Figure 2-1B). This was 
paralleled by a progressive increase in the ribosome recruitment of HA-eIF4E mRNA 
(Figure 2-1C). To validate that ectopic HA-eIF4E is functional we utilized a reporter 
mRNA construct in which translation of Renilla luciferase is cap-dependent (74) and 
observed a 63% increase in renilla luciferase after 24 hours (data not shown). To further 
validate that HA-eIF4E is functional we assessed its effects on ribosome loading by 
comparing polysome-profiles. After rendering 4E-inducible and non-inducible cells 
quiescent by serum deprivation we treated cells with mifepristone for 4h, a time point 
chosen to induce eIF4E expression 2-fold while minimizing counter-regulation (66). After 
treatment, equal amounts of ribosome-associated RNA were stabilized and stratified by 
ultracentrifugation through a sucrose gradient. Transcripts associated with ≥4 
ribosomes were pooled and defined as translationally active polysome-associated RNA 
(Figure 2-1D). We observed high quality polysome-associated RNA under all conditions 
in both cell lines indicating the absence of non-specific toxicity [RNA Integrity Number 
(RIN) for all samples was ≥ 7.1; average = 9.2, SD = 0.7]. In contrast to control cells, 4E-
inducible cells showed an increase in ribosome loading after mifepristone treatment, as 
indicated by the increased area under the absorbance plot in the region designated 
polysome-associated RNA (Figure 2-1D). Note that this comparison must be made 
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relative to the polysome peaks with 2-3 ribosomes, as the monosome peak is off-scale 
due to translational repression caused by serum deprivation. Thus 4E-inducible cells can 
rapidly increase levels of active HA-eIF4E protein, which in turn results in increased 
global translation. 
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Figure 2-1 An in vitro model for precise modulation of eIF4E activity 
(A) Time course of quiescent NIH 3T3 cells harboring an inducible eIF4E construct (“4E-
inducible” cells) after incubation with the inducing agent mifepristone (MIF, 625 pM) for the 
indicated time period. Cells were lysed and both ectopic (HA-tagged) and endogenous eIF4E 
were quantified by immunoblot. Actin is shown as a loading control. Numbers are relative 
optical density (OD). (B) Time course of total cellular ectopic HA-eIF4E mRNA expression. 
Quiescent cells were incubated with mifepristone (625pM) for up to 3 h, RNA purified and 
subjected to Q-PCR analysis. Data from the total mRNA fraction was normalized to a 0 h 
(baseline) value of 1.0. (C) Polysomal mRNA analysis of ectopic eIF4E expression. mRNA from 
mifepristone treated 4E-inducible cells was stratified on a sucrose gradient and fractionated into 
8 increasingly translationally active fractions, numbered 3 (lightest, fewest ribosomes bound) to 
10 (heaviest, most ribosomes bound). mRNA was quantified by Q-PCR as a function of time after 
induction. (D) Polysome tracings from 4E-inducible and non-inducible cells. RNA was collected 
from quiesced 4E-inducible and non-inducible cells treated for 4 h ± mifepristone. Shown is UV 
absorbance (254 nm) of cellular RNA stratified by ultracentrifugation on a sucrose gradient. 
Transcripts associated with ≥4 ribosomes are designated as heavily translated mRNA, hereafter 
defined as polysome-associated RNA, indicated by the bar. Shown are representative tracings of 
1-3 independent replicates of each treatment condition. 
To allow precise tuning of eIF4E activity within the 2-fold dynamic range we initially 
considered identifying a panel of cell lines with different maxima for eIF4E induction. 
However, such an approach would be limited by the possibility of non eIF4E-related 
differences between the clones. Instead we focused on a more robust approach where 
eIF4E activity is also modulated by a chemical inhibitor in the 4E-inducible cell line 
described above. To assess this potential of precisely tuning eIF4E activity using 
chemical agents we treated quiescent cells with an eIF4E inhibitor, 4Ei-1; concurrent 
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with induction of ectopic eIF4E expression. 4Ei-1 is rapidly bio-activated to the eIF4E cap 
binding inhibitor, 7-BnGMP, within 5 minutes (75). Consistent with its role as a 
translational repressor (73), 4Ei-1 elicited a dose-dependent (up to 200 µM) decrease in 
polysome-associated RNA (Figure 2-2A). The effect was not caused by general toxicity 
because total cellular RNA levels remained relatively constant across the entire dose-
range (Figure 2-2A). Further corroborating a specific effect of 4Ei-1 on translation, 4Ei-1 
treatment reduced cap-dependent translation in a dose-dependent manner in a cell-
free translation assay (Figure 2-2B). The stability of total cellular mRNA levels together 
with the presence of high quality intact polysomes in the presence of 4Ei-1 (Figure 2-3A) 
indicates that a non-specific toxic effect of 4Ei-1 on gene expression is unlikely. Thus this 
model system which combines robust and rapid increased expression of eIF4E with 
precise tuning of eIF4E activity using chemical inhibitors allows detailed studies of how 
eIF4E activity effects translation across the entire physiological expression range. 
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Figure 2-2 4Ei-1 decreases global translational activity. 
(A) Total cellular RNA and polysome-associated RNA as a function of 4Ei-1 concentration. Shown 
are the amounts of polysome-associated and total cellular RNA (normalized to cell number) 
calculated using UV absorbance at 260 nm. Data shown are from a representative replicate of 
one set of polysome preparations across the dose range of 4Ei-1. (B) Cap dependent 
translational activity of reticulocyte lysate incubated with 0 to 100 µM 4Ei-1. Renilla luciferase 
activity was measured in a Lumat luminometer with the Promega Dual-Luciferase Reporter 
System. Error bars indicate ± SD of quadruplicate samples from a single experiment. Results 
shown are representative of 3 experiments. 
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Figure 2-3 4Ei-1 treatment after eIF4E induction does not alter eIF4E protein levels or 
affect polysome quality 
(A) Polysome tracing from 4E-inducible cells. RNA was collected from quiesced 4E-inducible cells 
treated for 4 h with mifepristone + 200 μM 4Ei-1. Tracing shown is representative of 3 
independent replicates. (B) Representative Western blot of a time course of quiescent 4E-
inducible cells treated either with: mifepristone, mifepristone + 200 µM 4Ei-1, mifepristone + 
500 µM 4Ei-1, or untreated control. Cells were lysed and both ectopic (HA-tagged) and 
endogenous eIF4E was quantified by immunoblot. Actin is shown as a loading control. Shown is 
a representative example of 2 independent replicates. 
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4Ei-1 is bio-converted into 7-BnGMP 
4Ei-1 was bioactivated into 7-BnGMP in 4E-inducible cells (Figure 2-4B). Of note is that 
the 4Ei-1 standards prepared in Hepes showed slight degradation into 7-BnGMP or 
batch impurity, but the 7-BnGMP observed was only about 1% of the 4Ei-1 detected 
(Figure 2-4B,C). This 1% degradation was also seen in the cell-free media and therefore 
represents the 7-BnGMP baseline levels in the media treated with 4Ei-1. However, a 35-
fold enrichment of 7-BnGMP was seen in the cell-experienced media treated with 
500µM 4Ei-1 in DMEM, and a 70-fold enrichment was seen in the cell-experienced 
media treated with 500µM 4Ei-1 in defined media; indicating that the cells were actively 
bio-converting 4Ei-1 into 7-BnGMP. Interestingly, the baseline level of 7-BnGMP was 
also high in the cell-free media sample with 10% FBS, indicating active conversion of 4Ei-
1 into 7-BnGMP in the serum. Further analysis of this serum-mediated conversion will 
be complicated because the internal standard used to quantitate 4Ei-1 and 7-BnGMP 
was decreased by 23-52% exclusively in the serum-containing samples. Accumulation of 
intracellular 7-BnGMP and 4Ei-1 was increased in a dose-dependent manner by 
verapamil (Figure 2-4D, E), which blocks L-type calcium channels (76). To investigate the 
possibility that cellular bioconversion was not occurring but 4Ei-1 was degrading into 7-
BnGMP in the cell-experienced media due to a drop in pH caused by cellular biochemical 
processes, the pH of media treated for 4 hours was tested (Figure 2-4F). The pH of cell-
free and cell-experienced media was not significantly different, indicating that the cells 
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were likely bioconverting 4Ei-1 into 7-BnGMP and actively exporting it in a Ca2+ 
dependent manner. 
  26 
 
  27 
Figure 2-4 4Ei-1 is bio-converted into 7-BnGMP 
(A-C) 4E-inducible cells were plated at high density (serum starved samples were serum 
deprived with defined media for 24 hours prior to treatment) and then incubated at 37°C for 4 
hours with 500µM 4Ei-1 and as indicated. (DMEM = Dulbecco's Modified Eagle Medium, FBS = 
Fetal Bovine Serum, Verapamil = 100 µM.) Cells were lysed, and incubation (cell-experienced 
and cell-free) media was collected. All samples were run through an Acquity UPLC system and 
analyzed for 4Ei-1 and 7-BnGMP content on an electrospray triple-quadrupole mass 
spectrometer (Waters TQ Detector). The 10, 3.333, and 1 µg/ml 4Ei-1 samples indicate technical 
standards prepared in Hepes buffer. Error bars indicate triplicate biological replicates each 
analyzed with triplicate technical LCMS reads. (D-E) Samples were treated with mifepristone, 
500 µM 4Ei-1, and [0-250 µM] verapamil. All samples analyzed using methods above. (F) pH 
level of media treated as indicated and either kept in a 37°C water bath (untreated control), or 
incubated for 4 hrs at 37°C and 5% CO2 either with or without cells. Error bars indicate triplicate 
biological samples each read three times using a Corning Pinnacle 530 pH meter. 
Genome-wide translational analysis identifies differentially 
responding genes in response to precisely tuned eIF4E activity. 
To define the relative translational sensitivity of individual transcripts to precisely tuned 
eIF4E activity in the physiological range we compared genome-wide expression patterns 
across six different eIF4E-activity levels from a starting population of quiescent cells 
(Figure 2-5A). We orthogonally modulated eIF4E activity with a dual system: 
mifepristone induction of the 4E-inducible cell line to increase eIF4E protein level and 
activity and a dose range of 4Ei-1 to competitively inhibit eIF4E activity without altering 
eIF4E protein expression (Figure 2-4B). As the concentration of polysome-associated 
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RNA did not significantly change with 4Ei-1 concentrations above 200 µM (See Figure 
2-2A), a dose range of 4Ei-1 from 0 to 200 µM was chosen. Several controls were used 
including treatment with a 4Ei-1 analog, 4Ei-4 (has a 10-fold lower affinity for eIF4E as 
compared to 4Ei-1 (77)), at the highest used concentration to exclude drug class effects 
unrelated to eIF4E-5’mRNA cap antagonism; and non-inducible cells to exclude effects 
on translation caused by mifepristone. Due to the disparate mechanisms of action, an 
off-target effect from the 4Ei-1 drug treatment is unlikely to also be a non-eIF4E related 
effect of mifepristone treatment and we therefore did not examine this interaction. 
Both total cellular RNA and polysome-associated RNA were isolated from each condition 
(Figure 2-5A) and subsequently probed with DNA-microarrays. 
Since eIF4E affects gene expression primarily at the level of ribosome recruitment and 
not at the level of total cellular abundance (35, 66), we focused on the relationship 
between eIF4E activity and translation. However, polysome-associated RNA levels do 
not measure effects on translation directly. If transcript abundance increases, there can 
be an increase in the abundance of that transcript in the polysome pool without any 
change in translational activity in accordance with the laws of mass action. Therefore, to 
specifically estimate translation, the polysome-associated RNA level for each gene in 
each sample was corrected for the total cellular RNA level of that gene in each sample 
using ANOTA (see Methods).  
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We first compared the translation of 4E-inducible cells treated with mifepristone for 4h 
(therefore expressing eIF4E 2-fold above baseline) and treated ± 200 μM 4Ei-1 (with or 
without eIF4E inhibition). Consistent with the ability of 4Ei-1 to modulate translation 
through control of eIF4E activity, we found significant changes in translation indicated 
by an enrichment of genes with low p-values (Figure 2-5B). As expected when 
modulating eIF4E activity, the differential expression was more pronounced at the level 
of translation than at the level of total cellular RNA abundance (Figure 2-5C). 
Whereas previous genome-wide studies limited their analyses to overexpressed versus 
“normal” eIF4E, our approach provides us the possibility to identify genes whose 
translation are modulated by 4Ei-1 mediated inhibition of eIF4E activity and altered by 
increased eIF4E protein levels. This also allows elimination of genes showing non-
specific effects under each condition. We identified genes as significantly changed (p < 
0.05 in two separate tests) if they altered translation after 200 µM 4Ei-1 treatment and 
also when eIF4E protein level is modulated using mifepristone. In accordance with 
increased (induced eIF4E expression vs uninduced) and suppressed (4Ei-1 treatment vs 
no treatment) eIF4E activity, genes that are truly under eIF4E control when treated with 
4Ei-1 should modulate translation in the opposite direction when ectopic eIF4E is 
expressed. Indeed the majority of the genes (188/225) showed the expected inverse 
regulation pattern (Figure 2-5E). We expected that most of these 188 genes 
(significantly translationally altered by eIF4E activity) would parallel the activity of eIF4E 
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(i.e. suppressed translation by 4Ei-1 treatment and activated translation by increased 
eIF4E expression). In contrast to this assumption, but similar to several previous studies 
examining the effect of modulated eIF4F levels (35, 66, 70), we not only observed genes 
whose translation paralleled eIF4E activity (hereafter referred to as 4E hypersensitive, 
111 genes, Table 2-1) but also those that showed the opposite translation pattern 
(hereafter referred to as 4E hyposensitive, 77 genes, Table 2-2) (Figure 2-5D). Moreover, 
because equal amounts of total cellular and polysome-associated RNA were labeled and 
probed with the DNA-microarray for each sample, any global decrease in RNA 
expression is normalized and not observable when comparing the resulting relative 
microarray expression data. Therefore a “typical” gene which exhibited decreased 
translation mirroring the global decrease in translation after 4Ei-1 treatment, is found to 
be unchanged when comparing the equally loaded but differentially treated samples 
(Figure 2-5D, labeled “typical”). As a result the absolute effect on suppressed translation 
is underestimated with this approach which is designed to identify those genes showing 
larger translational effects than the typical gene. 
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Figure 2-5 Genome-wide translational analysis identifies differentially responding 
genes in response to precisely tuned eIF4E activity. 
(A) Genome-wide study design. Total cellular and polysome-associated samples were collected 
for each replicate and a “translational” module was generated which corrected polysome-
associated expression levels for mRNA abundance (see Methods). The 4E-inducible cell line is 
the experimental cell line with the non-inducible cell line acting as a mifepristone control, and 
4Ei-4 as a control for non-specific drug class effects of 4Ei-1. Equal amounts of RNA from each 
sample were analyzed by microarray. (B) Gene-by-gene p-value histogram comparing the 
translational modules of 4E-inducible cells treated with mifepristone to 4E-inducible cells 
treated with both mifepristone and 200 μM 4Ei-1. The dotted line indicates the null distribution. 
(C) Same analysis for total cellular RNA abundance. (D) Density plot of translational log2 fold 
changes elicited by 200 μM 4Ei-1 and mifepristone compared to mifepristone alone in 4E-
inducible cells. The black line represents genes not significantly altered by 4E induction and 4Ei-1 
treatment when comparing equally loaded microarrays, which normalizes the 4Ei-1 mediated 
decrease in overall polysome-associated RNA. These genes were defined as having a “typical” 
response to eIF4E modulation. The green line represents 4E hypersensitive genes and the blue 
line represents 4E hyposensitive genes (relative gene numbers for these sets 10x relative to 
typical genes). (E) Scatter plot of those genes identified as both: responsive to 4Ei-1 and 
responsive to 4E induction (p < 0.05 in both comparisons). The x-axis is log2 fold change due to 
200µM 4Ei-1 treatment in induced cells; the y-axis is log2 fold change due to mifepristone 
induction when compared to uninduced cells. The blue (4E hyposensitive) and green (4E 
hypersensitive) dots represent genes which display concordant behavior when treated with 4Ei-
1 and induced with mifepristone. 
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As the main goal of this study was to discover the chemical and biological characteristics 
of eIF4E responsive genes and because of the relatively permissive FDR threshold, we 
focused on identifying these two gene sets and not on identifying and characterizing the 
response of a particular gene to eIF4E. However, this unsupervised analysis did identify 
VEGF, a validated, eIF4E-responsive gene (43, 78). 
Translation of 4E hyposensitive and 4E hypersensitive genes is 4Ei-
1 dose-dependent. 
Next we assessed the effect of precisely tuned eIF4E activity on the translation of the 
identified 4E-hyper or –hypo sensitive genes sets by using concentrations of 4Ei-1 
between 0 and 200 µM. In theory if the sets are truly 4E-sensitive, as the 4Ei-1 
concentration is increased more significant genes will be detected when compared to 
the no 4Ei-1 baseline. Indeed, the 4E hypersensitive genes showed a dose dependent 
increase in the number of genes with low p-values (Figure 2-6A, note that all genes at 
the 200 µM dose exhibit p-values < 0.05 by definition). The 4E hyposensitive genes 
showed a similar 4Ei-1 dose dependent effect on translation (Figure 2-6B). This dose-
regulation relationship could have been caused by an increase in the fold-change 
differences for translation or a reduction in the experimental variance at higher 4Ei-1 
concentrations. To discriminate between the two we directly looked at translation fold-
changes. Indeed, such fold-changes are also dose-dependent, as 4E hypersensitive and 
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4E hyposensitive genes gradually return toward baseline (i.e. the translation in treated 
cells) with decreasing doses of 4Ei-1 (Figure 2-6C, D). In addition, at 10 µM 4Ei-1, the 4E 
hyposensitive genes did not exhibit significantly higher expression levels than the 
untreated control (p = 0.67) whereas the 4E hypersensitive genes showed slightly lower 
expression levels (p = 7.8 x 10-3). To exclude the possibility of a non-specific drug effect, 
we compared translational fold change in cells treated with 200 µM 4Ei-4. Consistent 
with an eIF4E-specific effect, 4E hypersensitive and 4E hyposensitive genes were 
substantially less responsive to 4Ei-4 than to 4Ei-1, indicating that the effect of 4Ei-1 on 
translational activity was specifically related to its ability to antagonize cap-binding and 
was unlikely to be a non-specific drug class effect (Figure 2-6C, D). As expected, when 
comparing all genes, there was very little coherent change across the dose range of 4Ei-
1 (Figure 2-6E). Thus, we have identified a set of genes that show true differential eIF4E 
translational sensitivity in response to precisely tuned eIF4E activity. 
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Figure 2-6 Translation of 4E hyposensitive and 4E hypersensitive genes is 4Ei-1 dose-
dependent. 
(A) Fraction of 4E hypersensitive genes (y-axis) passing a given p-value threshold (x-axis) 
comparing induced cells in the absence of 4Ei-1 to induced cells treated with: 200 µM 4Ei-1 
(black line), 100 µM 4Ei-1 (red line), 50 µM 4Ei-1 (blue line) or 10 µM 4Ei-1 (green line). The 
dotted line represents the theoretical null distribution. P-values are calculated from Wilcoxon 
signed ranked test and compare the indicated dose with the previous concentration (e.g. the 10 
µM line is the comparison of 10 µM to the theoretical null distribution). (B) The same analysis is 
shown for 4E hyposensitive genes. (C) Translational log2 fold changes induced by [0 – 200] µM 
4Ei-1 or 200 µM 4Ei-4 on the 4E hypersensitive genes. The p-values shown compare each dose 
with the next lowest concentration (paired Wilcoxon signed ranked test used). (D) The same 
analysis is shown for 4E hyposensitive genes. (E) The same analysis for all 7,201 genes detected 
in our system. 
4E hyposensitive and 4E hypersensitive genes have distinct 
sequence characteristics. 
To elucidate the structural features that distinguish transcripts within the 4E 
hypersensitive and 4E hyposensitive gene lists, we analyzed the 5’ and 3’ UTRs of both 
sets for length and GC content, and 3’ UTRs for microRNA binding sites. In contrast to 
the most recent reports suggesting that 4F-sensitive mRNAs have short 5’UTRs (70, 71), 
this analysis revealed that 4E hypersensitive genes had longer 5’UTRs compared to the 
typical responding genes, and the same held true when comparing the typical genes to 
4E hyposensitive genes (Figure 2-7A). A similar pattern was observed for 5’UTR GC 
content (Figure 2-7B). Moreover, 4E hypersensitive genes displayed increased 3’UTR 
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length (Figure 2-7C), but decreased GC content in their 3’UTRs (Figure 2-7D), contrary to 
what was seen in their 5’ UTRs. When examining microRNA target number in the 
3’UTRs, we found that 4E hypersensitive genes exhibited increased numbers of unique 
microRNA target sites compared to typical genes (Figure 2-7E); even after correction for 
3’UTR length (Figure 2-7F). These findings reestablish the importance of structural 
features within the 5’ UTR for 4E sensitive translation. 
  38 
 
  39 
Figure 2-7 4E hyposensitive and 4E hypersensitive genes have distinct sequence 
characteristics. 
Shown are sequence characteristics of 4E hypersensitive genes and 4E hyposensitive genes 
compared to typical genes. P-values were calculated using the Mann-Whitney U test. (A) 4E 
hypersensitive genes have longer 5'UTRs (p = 2.7 x 10-2) and 4E hyposensitive genes trend 
toward shorter 5'UTRs (p = 2.0 x 10-1). (B) 4E hypersensitive genes trend toward higher GC 
content in their 5'UTRs (p = 1.2 x 10-1) and 4E hyposensitive genes have lower GC content (p = 
4.9 x 10-2). (C) 4E hypersensitive genes have longer 3'UTRs (p = 5.5 x 10-6) and 4E hyposensitive 
genes have shorter 3'UTRs (p = 1.2 x 10-2). (D) 4E hypersensitive genes have lower 3'UTR GC 
content (p = 4.2 x 10-7) and 4E hyposensitive genes have higher 3'UTR GC content (p = 2.6 x 10-4). 
(E) 4E hypersensitive genes have more unique microRNA target sites (1.0 x 10-7); 4E 
hyposensitive genes have fewer microRNA target sites (p = 1.8 x 10-3). (F) After correcting for the 
3'UTR length, the 3'UTRs of 4E hypersensitive genes are more densely populated with microRNA 
target sites (p = 1.7 x 10-4) and the 3'UTRs of 4E hyposensitive genes are more sparsely 
populated with microRNA target sites (p = 9.2 x 10-3). 
Characteristics associated with eIF4E hypersensitivity predict the 
genome-wide translational response across the physiological eIF4E 
activity range.  
In the previous section we identified the features of eIF4E hypersensitive genes: longer 
5'UTRs with higher GC content, longer 3'UTRs with lower GC content and more unique 
microRNA targets even after correction for 3'UTR length. To assess whether these 
features are sufficient to explain 4E-hypersensitive translation across the 4Ei-1 dose 
range we removed the identified 4E hypo- and hyper-sensitive genes and analyzed these 
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features to see if they predicted the translational response. To that end, we divided the 
7,201 genes we detected into deciles based on the criteria analyzed. Note that each 
decile contains many more genes than the 4E hypersensitive gene list (111 genes). 
Although there was substantial variation, we found that transcripts in the highest decile 
of 5’ UTR length (> 403 nt), on average showed a decrease in translational fold-change 
with increasing doses of 4Ei-1 (Figure 2-8A). Similarly, transcripts in the highest decile of 
5’ UTR GC content (> 77%) showed a decrease in translational fold-change with 
increasing doses of 4Ei-1 (Figure 2-8B). This dose dependence was also true for the 
3’UTR features. Transcripts in the highest decile of 3’ UTR length (> 2898 nt) showed a 
decrease in translational fold-change with increasing doses of 4Ei-1 (Figure 2-8C); and 
transcripts in the lowest decile of 3’ UTR GC content (< 35%) showed a decrease in 
translational fold-change with increasing doses of 4Ei-1 (Figure 2-8D). We also examined 
the relationship between microRNAs and eIF4E sensitivity and found that transcripts 
with greater than 10 unique microRNA target family seed regions in their 3’UTR showed 
a decrease in translational fold-change with increasing doses of 4Ei-1 (Figure 2-8E). All 
these findings are consistent with the observed sequence characteristics of 4E hyper- 
and hypo-sensitive genes. 
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Figure 2-8 Characteristics associated with eIF4E hypersensitivity predict the genome-
wide translational response across the physiological eIF4E activity range. 
For each structural characteristic of 4E hypersensitive genes identified in Figure 2-7, after 
removing the 4E hypersensitive and 4E hyposensitive gene sets the set of transcripts in the top 
decile of each characteristic was collected from among the 7,201 genes detected in our system. 
For each gene set, 4E hypersensitivity was evident when cells were treated with 200 µM of 4Ei-1 
(p-value in legend indicates comparison of genes in top decile in specified category to all other 
genes), and expression reverted toward baseline with decreasing dosage of 4Ei-1. Gene sets 
tested were: (A) transcripts with >403 nt in their 5’UTR (p = 1.1 x 10-8), (B) transcripts with >77% 
GC content in their 5’UTR (p = 1.8 x 10-7), (C) transcripts with >2898 nt in their 3’UTR (p = 6.3 x 
10-11), (D) transcripts with <35% GC content in their 3’UTR (p = 5.5 x 10-18), and (E) transcripts 
with >10 unique microRNA targets (p = 2.0 x 10-19). 
To investigate the role of specific sequence-based 3’UTR characteristics on the 4Ei-1 
translational response, we analyzed the 3’UTRs of all detected genes for AU-rich and 
GU-rich elements. AU-rich elements are cis-acting short sequences that mediate 
recognition of an array of RNA-binding proteins and affect mRNA stability and 
translation (79). Another mechanism of 3’UTR regulated stability is found on transcripts 
containing the consensus GU-rich sequence of “UGUUUGUUUGU” (80) and GU-rich 
repeats (81), both of which elicit rapid CELF1-mediated mRNA decay. We found that 
genes with either AU-rich (p = 1.4 x 10-15) or GU-rich sequences (p = 0.014) exhibited a 
decrease in translational fold change with increasing doses of 4Ei-1 (Figure 2-9A, B), 
supporting the link between 3’UTR mediated translational suppression and 4E 
hypersensitivity, especially for AU-rich elements. 
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Figure 2-9 4Ei-1 treatment decreases the translation of genes with AU-rich sequences 
and GU-rich sequences. 
(A) Translational log2 fold changes induced by [0 – 200] µM 4Ei-1 or 200 µM 4Ei-4 on genes with 
AU-rich elements. The p-values shown in the figure compare each dose with the next lowest 
concentration (paired Wilcoxon signed ranked test used). 4Ei-1 sensitivity was especially evident 
when cells were treated with 200 µM of 4Ei-1 (p = 1.4 x 10-15 comparing genes with AU-rich 
elements to genes without them) (B) Same translational log2 fold change with GU-rich elements 
(p = 0.014). 
eIF4E hypersensitive genes are associated with cell proliferation. 
To identify cellular functions associated with 4E hypersensitive and 4E hyposensitive 
genes, we used Gene Ontology annotations to determine ontologies that were over-
represented in our 4E hypersensitive and 4E hyposensitive gene lists (FDR < 0.1) (Figure 
2-10A). Among the significant ontologies, “regulation of proliferation” was 
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overrepresented in the 4E hypersensitive gene list; a result in accord with reports that 
4E-hypersensitive mRNAs commonly encode proto-oncogenic, proliferation, and survival 
promoting proteins (82). To probe proliferation functionally, we induced eIF4E and 
performed cell cycle analysis across the 4Ei-1 dose range. After eIF4E induction, we 
observed a 5-fold increase in the proportion of cells in S phase or G2/M (Figure 2-10B), 
although the absolute numbers of the induced cycling cells were small. 4Ei-1 
significantly decreased the percentage of cycling cells in a dose dependent manner (p 
<0.0001 at 80, 200, and 500 µM 4Ei-1; p <0.01 at 12 µM 4Ei-1). Of note, 4Ei-1 treatment 
of uninduced cells did not significantly decrease the basal level of cell cycle transit (two-
tailed unpaired t-test, p = 0.19) (Figure 2-10B), and mifepristone treatment of non-
inducible cells had no impact on cell cycle distribution (Figure 2-11). Therefore, in accord 
with enrichment of the “regulation of proliferation” ontology, eIF4E induction drives a 
small proportion of quiescent fibroblasts into the cell cycle and 4Ei-1 attenuates this 
effect. 
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Figure 2-10 eIF4E hypersensitive genes are associated with cell proliferation. 
(A) Gene ontologies that are over-represented in the 4E hypersensitive and 4E hyposensitive 
genes (FDR < 0.1, calculated using Fisher's exact test). (B) Cell cycle transit of quiescent 4E-
inducible cells pre-treated for 4 h with the indicated concentrations of 4Ei-1 with treatment 
continued for 24 h as indicated. DNA content was quantified by flow cytometry using Hoechst 
33258. Shown is the percent of cells in S+G2/M and is a representative replicate of 3 
independent experiments. Error bars indicate ±SD of quadruplicate samples from a single 
experiment. Serum deprived cells in defined media were used as an untreated negative control 
and 1 nM PDGF as a positive control. **** = p <0.0001 versus MIF induction alone. ** = p <0.01 
versus MIF induction alone. 
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Figure 2-11 Mifepristone treatment has no effect on cell cycle transit in non-inducible 
cells. 
Cell cycle transit of quiescent non-inducible and 4E-inducible cells treated for 24 h as indicated. 
DNA content was quantified by flow cytometry using Hoechst 33258. Shown is the percent of 
cells in S+G2/M, and is a representative replicate of 3 independent experiments. Error bars 
indicate ±SD of quadruplicate samples from a single experiment. Serum deprived cells in defined 
media were used as an untreated control and 1 nM PDGF as a positive control. 
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Table 2-1 List of 4E Hypersensitive Genes 
Gene ID Gene Symbol Gene Name 
68497 1110018G07Rik RIKEN cDNA 1110018G07 gene 
11477 Acvr1 activin A receptor, type 1 
66549 Aggf1 angiogenic factor with G patch and FHA domains 1 
98404 AI597479 expressed sequence AI597479 
23802 Amfr autocrine motility factor receptor 
245886 Ankrd27 ankyrin repeat domain 27 (VPS9 domain) 
11773 Ap2m1 adaptor protein complex AP-2, mu1 
320982 Arl4c ADP-ribosylation factor-like 4C 
65105 Arl6ip4 ADP-ribosylation factor-like 6 interacting protein 4 
76976 Arxes2 adipocyte-related X-chromosome expressed sequence 2 
12069 Bex2 brain expressed X-linked 2 
12166 Bmpr1a bone morphogenetic protein receptor, type 1A 
12328 Caml calcium modulating ligand 
12340 Capza1 capping protein (actin filament) muscle Z-line, alpha 1 
12389 Cav1 caveolin 1, caveolae protein 
67282 Ccdc53 coiled-coil domain containing 53 
227210 Ccnyl1 cyclin Y-like 1 
12696 Cirbp cold inducible RNA binding protein 
12753 Clock circadian locomotor output cycles kaput 
98417 Cnih4 cornichon homolog 4 (Drosophila) 
12816 Col12a1 collagen, type XII, alpha 1 
67876 Coq10b coenzyme Q10 homolog B (S. cerevisiae) 
12859 Cox5b cytochrome c oxidase, subunit Vb 
70425 Csnk1g3 casein kinase 1, gamma 3 
217615 Ctage5 CTAGE family, member 5 
99375 Cul4a cullin 4A 
22428 Dctn6 dynactin 6 
19347 Dennd5a DENN/MADD domain containing 5A 
386655 Eid2 EP300 interacting inhibitor of differentiation 2 
14042 Ext1 exostoses (multiple) 1 
14062 F2r coagulation factor II (thrombin) receptor 
226016 Fam108b family with sequence similarity 108, member B 
399558 Flrt2 fibronectin leucine rich transmembrane protein 2 
71375 Foxn3 forkhead box N3 
14573 Gdnf glial cell line derived neurotrophic factor 
629364 Gm16372 actin related protein 2/3 complex, subunit 5 pseudogene 
638695 Gm7247 predicted gene 7247 
14874 Gstz1 glutathione transferase zeta 1 (maleylacetoacetate isomerase) 
14913 Guca1a guanylate cyclase activator 1a (retina) 
50708 Hist1h1c histone cluster 1, H1c 
98758 Hnrnpf heterogeneous nuclear ribonucleoprotein F 
17082 Il1rl1 interleukin 1 receptor-like 1 
16179 Irak1 interleukin-1 receptor-associated kinase 1 
74158 Josd1 Josephin domain containing 1 
107351 Kank1 KN motif and ankyrin repeat domains 1 
16600 Klf4 Kruppel-like factor 4 (gut) 
77889 Lbh limb-bud and heart 
218454 Lhfpl2 lipoma HMGIC fusion partner-like 2 
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29806 Limd1 LIM domains containing 1 
16974 Lrp6 low density lipoprotein receptor-related protein 6 
226778 Mark1 MAP/microtubule affinity-regulating kinase 1 
69790 Med30 mediator complex subunit 30 
66213 Med7 mediator complex subunit 7 
56615 Mgst1 microsomal glutathione S-transferase 1 
381269 Mreg melanoregulin 
66448 Mrpl20 mitochondrial ribosomal protein L20 
50529 Mrps7 mitchondrial ribosomal protein S7 
74026 Msl1 male-specific lethal 1 homolog (Drosophila) 
67154 Mtdh metadherin 
100044124 NA NA 
100044475 NA NA 
100044862 NA NA 
100046953 NA NA 
100047184 NA NA 
100047670 NA NA 
100048622 NA NA 
633016 NA NA 
76522 Naa38 N(alpha)-acetyltransferase 38, NatC auxiliary subunit 
17973 Nck1 non-catalytic region of tyrosine kinase adaptor protein 1 
66866 Nhlrc2 NHL repeat containing 2 
20409 Ostf1 osteoclast stimulating factor 1 
76073 Pcgf5 polycomb group ring finger 5 
14755 Pigq phosphatidylinositol glycan anchor biosynthesis, class Q 
72084 Pigx phosphatidylinositol glycan anchor biosynthesis, class X 
18764 Pkd2 polycystic kidney disease 2 
71801 Plekhf2 pleckstrin homology domain containing, family F member 2 
19053 Ppp2cb protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform 
103554 Psme4 proteasome (prosome, macropain) activator subunit 4 
28193 Reep3 receptor accessory protein 3 
73296 Rhobtb3 Rho-related BTB domain containing 3 
69581 Rhou ras homolog gene family, member U 
59044 Rnf130 ring finger protein 130 
19822 Rnf4 ring finger protein 4 
78294 Rps27a ribosomal protein S27A 
20104 Rps6 ribosomal protein S6 
20168 Rtn3 reticulon 3 
50724 Sap30l SAP30-like 
107767 Scamp1 secretory carrier membrane protein 1 
58172 Sertad2 SERTA domain containing 2 
107723 Slc12a6 solute carrier family 12, member 6 
69048 Slc30a5 solute carrier family 30 (zinc transporter), member 5 
268996 Ss18 synovial sarcoma translocation, Chromosome 18 
226551 Suco SUN domain containing ossification factor 
24071 Synj2bp synaptojanin 2 binding protein 
83671 Sytl2 synaptotagmin-like 2 
21813 Tgfbr2 transforming growth factor, beta receptor II 
72098 Tmem68 transmembrane protein 68 
74493 Tnks2 tankyrase, TRF1-interacting ankyrin-rel. ADP-ribose polymerase 2 
21983 Tpbg trophoblast glycoprotein 
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22031 Traf3 TNF receptor-associated factor 3 
68842 Tulp4 tubby like protein 4 
65960 Twsg1 twisted gastrulation homolog 1 (Drosophila) 
53330 Vamp4 vesicle-associated membrane protein 4 
22339 Vegfa vascular endothelial growth factor A 
232023 Vopp1 vesicular, overexpressed in cancer, prosurvival protein 1 
66840 Wdr45l Wdr45 like 
215280 Wipf1 WAS/WASL interacting protein family, member 1 
22418 Wnt5a wingless-related MMTV integration site 5A 
383295 Ypel5 yippee-like 5 (Drosophila) 
142682 Zcchc14 zinc finger, CCHC domain containing 14 
170737 Znrf1 zinc and ring finger 1 
   
4E hypersensitive genes are defined as genes which have a p-value < 0.05 and a decrease in 
relative expression when comparing 4E-inducible cells treated only with mifepristone to 4E-
inducible cells treated with both mifepristone and 200 μM 4Ei-1, as well as an increase in 
expression (p < 0.05) when comparing untreated 4E-inducible cells to 4E-inducible cells treated 
only with mifepristone. 
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Table 2-2 List of 4E Hyposensitive Genes 
Gene ID Gene Symbol Gene Name 
234734 Aars alanyl-tRNA synthetase 
27406 Abcf3 ATP-binding cassette, sub-family F (GCN20), member 3 
11370 Acadvl acyl-Coenzyme A dehydrogenase, very long chain 
104112 Acly ATP citrate lyase 
329910 Acot11 acyl-CoA thioesterase 11 
27360 Add3 adducin 3 (gamma) 
11669 Aldh2 aldehyde dehydrogenase 2, mitochondrial 
214579 Aldh5a1 aldhehyde dehydrogenase family 5, subfamily A1 
235606 Apeh acylpeptide hydrolase 
16801 Arhgef1 Rho guanine nucleotide exchange factor (GEF) 1 
102098 Arhgef18 rho/rac guanine nucleotide exchange factor (GEF) 18 
210004 B3gntl1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1 
224727 Bag6 BCL2-associated athanogene 6 
239368 BC030476 cDNA sequence BC030476 
12036 Bcat2 branched chain aminotransferase 2, mitochondrial 
140721 Caskin2 CASK-interacting protein 2 
67179 Ccdc25 coiled-coil domain containing 25 
386463 Cdsn corneodesmosin 
83429 Ctns cystinosis, nephropathic 
218581 Depdc1b DEP domain containing 1B 
66233 Dmap1 DNA methyltransferase 1-associated protein 1 
13433 Dnmt1 DNA methyltransferase (cytosine-5) 1 
70601 Ecd ecdysoneless homolog (Drosophila) 
110147 Ehmt2 euchromatic histone lysine N-methyltransferase 2 
13667 Eif2b4 eukaryotic translation initiation factor 2B, subunit 4 delta 
77938 Fam53b family with sequence similarity 53, member B 
12091 Glb1 galactosidase, beta 1 
277333 Gm5069 glyceraldehyde-3-phosphate dehydrogenase pseudogene 
384710 Gm5340 acidic ribosomal phosphoprotein P0 pseudogene 
666036 Gm7901 3-phosphoglycerate dehydrogenase pseudogene 
76238 Grhpr glyoxylate reductase/hydroxypyruvate reductase 
433943 Gstm2-ps1 glutathione S-transferase mu 2 (muscle), pseudogene 1 
98053 Gtf2f1 general transcription factor IIF, polypeptide 1 
72748 Hdhd3 haloacid dehalogenase-like hydrolase domain containing 3 
78908 Igsf3 immunoglobulin superfamily, member 3 
210146 Irgq immunity-related GTPase family, Q 
193796 Kdm4b lysine (K)-specific demethylase 4B 
16211 Kpnb1 karyopherin (importin) beta 1 
235497 Leo1 Leo1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) 
217325 Llgl2 lethal giant larvae homolog 2 (Drosophila) 
16905 Lmna lamin A 
17688 Msh6 mutS homolog 6 (E. coli) 
192156 Mvd mevalonate (diphospho) decarboxylase 
637711 NA NA 
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17995 Ndufv1 NADH dehydrogenase (ubiquinone) flavoprotein 1 
100608 Noc4l nucleolar complex associated 4 homolog (S. cerevisiae) 
230082 Nol6 nucleolar protein family 6 (RNA-associated) 
68323 Nudt22 nudix (nucleoside diphosphate linked moiety X)-type motif 22 
18293 Ogdh oxoglutarate dehydrogenase (lipoamide) 
12304 Pdia4 protein disulfide isomerase associated 4 
216134 Pdxk pyridoxal (pyridoxine, vitamin B6) kinase 
75273 Pelp1 proline, glutamic acid and leucine rich protein 1 
18624 Pepd peptidase D 
18641 Pfkl phosphofructokinase, liver, B-type 
54381 Pgcp plasma glutamate carboxypeptidase 
57435 Plin4 perilipin 4 
70428 Polr3b polymerase (RNA) III (DNA directed) polypeptide B 
56031 Ppie peptidylprolyl isomerase E (cyclophilin E) 
19089 Prkcsh protein kinase C substrate 80K-H 
68879 Prpf6 PRP6 pre-mRNA splicing factor 6 homolog (yeast) 
19182 Psmc3 proteasome (prosome, macropain) 26S subunit, ATPase 3 
19185 Psmd4 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 
97541 Qars glutaminyl-tRNA synthetase 
223864 Rapgef3 Rap guanine nucleotide exchange factor (GEF) 3 
68272 Rbm28 RNA binding motif protein 28 
20227 Sart1 squamous cell carcinoma antigen recognized by T cells 1 
378702 Serf2 small EDRK-rich factor 2 
66354 Snw1 SNW domain containing 1 
20322 Sord sorbitol dehydrogenase 
108903 Tbcd tubulin-specific chaperone d 
19241 Tmsb4x thymosin, beta 4, X chromosome 
231712 Trafd1 TRAF type zinc finger domain containing 1 
15547 Trmt2a TRM2 tRNA methyltransferase 2 homolog A (S. cerevisiae) 
22271 Upp1 uridine phosphorylase 1 
22283 Ush2a Usher syndrome 2A (autosomal recessive, mild) 
80743 Vps16 vacuolar protein sorting 16 (yeast) 
22594 Xrcc1 X-ray repair complementing defective repair in Chinese hamster cells 1 
   
4E Hyposensitive genes are defined as genes which have a p-value < 0.05 and an increase in 
relative expression when comparing 4E-inducible cells treated only with mifepristone to 4E-
inducible cells treated with both mifepristone and 200 μM 4Ei-1, as well as an decrease in 
expression (p < 0.05) when comparing untreated 4E-inducible cells to 4E-inducible cells treated 
only with mifepristone. 
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Discussion 
Most genome-wide studies examining eIF4E function have used constitutive over 
expression to study the long term effects of eIF4E activation and found eIF4E-sensitive 
genes had longer 5’UTR’s. However, recent studies used chemical inhibition of mTOR 
and found that eIF4F-sensitive genes had shorter 5’UTR’s. Here we probe this issue by 
rapidly increasing global translational activity with eIF4E induction in quiescent cells. In 
addition, we utilized the eIF4E chemical inhibitor 4Ei-1 to tune eIF4E activity in a dose-
dependent fashion, allowing us to examine gene expression across a range of eIF4E 
activities. Using this novel two-pronged system, we identified both 4E hypersensitive 
genes (more responsive to eIF4E activity than average) and 4E hyposensitive genes (less 
responsive to eIF4E activity than average). Both of these gene sets were validated by 
observing a coherent pattern of 4Ei-1 dose-dependence. We determined the structural 
characteristics associated with each of these classes: eIF4E hypersensitive genes tended 
to have longer 5'UTRs with higher GC content, longer 3'UTRs with lower GC content, 
higher density of unique microRNA target sites, and more AU-rich elements. These 
mRNA characteristics were also predictive of the translational response of all 7,201 
detected genes across the tested dose range of 4Ei-1. 
Increased eIF4F activity has been proposed to stimulate the translation of mRNAs with 
highly structured 5′UTRs through several possible mechanisms including the inability of 
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these mRNAs to compete for eIF4E, elicit formation of the eIF4F complex, retain the 
eIF4F complex, recruit ribosomes, or unwind mRNA (or some combination of these 
properties) compared with mRNAs without highly structured 5′UTRs (36). Our results 
address this directly at the level of eIF4E by modulating eIF4E abundance and its cap 
binding function. Increased eIF4E activity has been shown to selectively activate the 
translation of transcripts with longer 5’UTRs (83). Our finding that 4E hypersensitive 
genes tend to have increased 5’UTR GC content is in accord with previous studies 
showing that as the complexity of the 5′UTR is reduced, there is a loss of sensitivity for 
eIF4E in their translation (84). Consistent with this, in a polyelectrostatic model of 
protein-mRNA interactions, genes with up-regulated translational efficiencies in the 
caf20∆ (yeast 4E-BP homologue) mutant have high 5’UTR secondary structure and are 
longer (85). As the 4E-BPs function to negatively regulate eIF4E, this data is in general 
accord with our result that 4E hypersensitive genes possess higher 5’UTR secondary 
structure and length. This is in contrast with studies indicating that eIF4E targeted genes 
contain shorter 5’UTRs (70, 71, 86). Such inconsistencies may arise due to significant 
differences among experimental systems which reflect true biological differences in the 
state of the translational pathway under those conditions. In particular, systems 
featuring inducible eIF4E activity differ from systems with constitutively active eIF4E in 
which cells have had the opportunity to counter the effects of eIF4E over expression 
(66, 86). Other than our unique two-pronged system utilizing eIF4E-5’mRNAcap 
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antagonism, other differences from our system include the use of: human telomerase 
reverse transcriptase (hTERT) immortalized human mammary epithelial cells (66, 86), 
non-quiescent cells (66, 86), different number of ribosomes collected as the polysome-
associated pool (5, 35), and ribosome profiling (70, 71). It is plausible that in these 
altered regulatory environment, eIF4E hypersensitive genes may exhibit a distinct set of 
structural features and these features may be distinct from those regulated directly by 
mTOR. Interestingly, when we looked at other known 5’UTR regulatory features, such as 
the 5'-TOP (5'-terminal oligopyrimidine tract) regulatory element (87), and despite 
recent data identifying TOP or TOP-like motifs as the key and almost ubiquitous 
regulatory characteristic of mTORC1-regulated mRNAs (70), we found no significant 
5’TOP enrichment in our 4E hyposensitive and 4E hypersensitive genes. A likely 
explanation is that the set of translationally regulated genes is substantially different in 
these environments: direct downregulation of mTORC1 activity in rapidly proliferating 
cells in full serum with fully activated eIF4E activity (a status akin to many established 
cancers (88)) and inhibition of the eIF4E-5’mRNAcap association in quiescent serum 
deprived cells with low eIF4E activity (a status akin to physiological tissue repair and 
regeneration and cancer genesis). Thus our study provides additional context and 
complements established literature. 
When probing the 3’UTRs of eIF4E hypersensitive mRNAs, we found that they tended to 
have longer 3’UTRs with less GC content; again in contrast to observations made in cells 
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with constitutive eIF4E activation (86). However, as evidenced by the much lower p-
values for 3’UTR structural features compared to 5’UTR features, our data reinforced 
the concept that eIF4E hypersensitive transcripts are more likely to be translationally 
regulated through their 3’UTRs (86). One interpretation of this result is that increased 
3’UTR length and decreased complexity allow increased microRNA regulation of these 
transcripts, in accord with our result showing increased microRNA target density in 4E 
hypersensitive transcripts. This parallels data showing that eIF4E is a component of 
processing-bodies (PB) and stress granules, implying that it plays a role in mRNA 
sequestration and/or turnover (89, 90). RNAi-mediated knockdown experiments reveal 
that a subset of P body factors, including eIF4E-T (eIF4E-transporter), LSm1, rck/p54, 
and Ccr4 are required for the accumulation of eIF4E in P bodies (91).  Processing bodies 
also contain mRNA but lack other pre-initiation factors. Instead, they contain microRNAs 
and a number of proteins associated with mRNA decay (e.g. DCP1a, DCP2, hedls/GE-1, 
p54/RCK, argonaute) and transport (e.g. FAST, RAP-55, TTP) allowing shepherding of 
specific mRNA transcripts between the translation and decay machineries (92). TTP 
binds to AU-rich elements in the 3'UTR’s of mRNA and promotes their degradation (93). 
eIF4E hypersensitive genes are enriched in AU (i.e. they are low in GC), and we found 
that genes containing AU-rich elements exhibited a decrease in translation after 4Ei-1 
treatment. These data support a model in which eIF4E selects specific mRNAs for 
translation, degradation, or sequestration based on their 3’UTR sequence 
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characteristics. Increased eIF4E activity may be able to rescue 4E hypersensitive 
transcripts from 3’UTR controlled translational suppression which occurs through 
multiple mechanisms including AU-rich elements, GU-rich elements, or microRNAs. 
Further analysis of those protein and mRNAs that associate with eIF4E in processing 
bodies will be necessary to further develop this model. 
A goal of our experiments was to elucidate the biological characteristics of 4E 
hypersensitive genes as a group. To this end, we probed for biological processes 
associated with eIF4E hypersensitive genes, searching for gene ontologies that were 
particularly enriched in this gene set. Of particular interest, we identified the gene 
ontology “regulation of proliferation”, a finding we functionally validated by showing 
that eIF4E induction increases proliferation and 4Ei-1 attenuates this effect. This result 
aligns with previous data showing that 4Ei-1 suppresses proliferation in CD4+ T-cells 
(77). In our system, 4Ei-1 was able to affect cell cycle transit at doses as low as 12 µM in 
contrast to the much higher doses needed to suppress T-cell proliferation. This result 
indicates that 4Ei-1 is effective at lower doses in our fibroblast system, particularly in 
the biologically relevant context of quiescence. Multiple genes in the “regulation of 
proliferation” ontology have previously been validated as translationally regulated 
genes. These included Tgfbr2 (transforming growth factor, beta receptor II), a gene we 
identified as 4E hypersensitive and which has been previously validated as 
translationally controlled during rat lung development (94). Another gene in the 
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“regulation of proliferation” ontology is MIF (macrophage migration inhibitory factor), a 
gene we identified as 4Ei-1 hypersensitive and which was previously validated as 4E 
sensitive after eIF4E induction (35). Our result showing the eIF4E sensitivity of 
proliferation genes also provides an explanation for why exogenous eIF4E mRNA 
augments wound healing (95). 
This search for biological processes also identified 4E hyposensitive genes as enriched in 
components of the spliceosomal complex, aligning with previous reports linking 
spliceosomal function to eIF4G; independent of its association with eIF4E (96). A 
separate nuclear pool of eIF4G stably associates with spliceosomes in vitro and shows 
close association with spliceosomal snRNPs and splicing factors in vivo (97). This 
complex may be recruited to pre-mRNAs via its interaction with the nuclear cap-binding 
complex (CBC) and accompany the mRNA to the cytoplasm, facilitating the switching of 
CBC for eIF4F (96). Therefore, it is expected that spliceosomal function and the 
translation of its components should be independent of eIF4E activity. This is in accord 
with the established precept that the expression of genes associated with homeostatic 
cellular functions (including the other hyposensitive ontology, “metabolic process”) are 
relatively insulated from changes in eIF4E activity and are translated at relatively 
constant rates (33). 
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Our experimental system provides several advantages compared to previous studies. 
The rapid induction of eIF4E expression after mifepristone treatment is not only faster 
but produces a more constant protein expression over time than previously published 
tetracycline-inducible eIF4E 3T3 cells (35). To reduce off-target effects and false 
positives in our list of hypersensitive and hyposensitive genes, we exploited the fact that 
induction increases eIF4E activity by altering protein level; whereas 4Ei-1 decreases 
eIF4E activity by competing for the 5’ cap. This enabled us to modulate eIF4E activity in 
orthogonal ways. Although it has been shown in epithelial cancer cell lines that 
extended 4Ei-1 treatment (24-72 hrs) is capable of decreasing eIF4E protein levels by 
initiating eIF4E proteasomal degradation (75), we did not observe this in our cells after 4 
hours. Further, the use of a dose-range of 4Ei-1 allowed us to validate the behavior of 
the hypersensitive and hyposensitive genes lists across a range of eIF4E activity. The 
two-pronged approach used here could also detect eIF4E hypersensitive genes in other 
cell types and in vivo models. This approach could be expanded to proteins other than 
eIF4E which have selective small molecule inhibitors available, and a dose range of the 
inhibitor could be combined with an inducible expression system to powerfully detect 
genome-wide effects from carefully tuned expression of the translational machinery 
component of interest. 
  
  59 
Materials & Methods 
Cell culture 
NIH 3T3 cell derivatives were maintained at 37oC, 5% CO2 in growth medium [Dulbecco's 
modified Eagle's medium high-glucose (DMEM, Sigma-Aldrich) supplemented with 10% 
fetal bovine serum (FBS, Sigma-Aldrich), 25mM Hepes, 100 units/ml penicillin, 100 
units/ml streptomycin and 125 ng/ml amphotericin (Life Techologies)]. 
Cell transfection 
Cells were seeded into 35 mm wells of 6-well clusters. After 24 h, cells were transfected 
with 4 μg DNA using Lipofectamine 2000 reagent (Life Technologies) according to the 
manufacturer's instructions. Cells were incubated in the presence of Lipofectamine 2000 
for 6 h, switched to DMEM containing 5% FBS for 24 h, and cultures were continued in 
growth medium until use. 
Inducible eIF4E system 
The inducible GeneSwitch system functions by expressing a truncated human 
progesterone receptor ligand-binding domain which can be bound by mifepristone, 
triggering a conformational change in the GeneSwitch protein, formation of an active 
homodimer,  transcription of the transgene and production of the protein of interest 
  60 
(98). GeneSwitch NIH 3T3 cells were purchased from Invitrogen and maintained in 
growth medium supplemented with hygromycin (50µg/ml) at 37oC, 5% CO2. Plasmids 
encoding hemagglutinin (HA)-tagged wild-type eIF4E [pKAS8-3] were linearized by 
digesting with SspI and transfected into GeneSwitch NIH 3T3 cells in log phase growth. 
Two days post-transfection, cells were subcultivated and zeocin selection begun (500 
µg/ml zeocin). Transfected cells were incubated at 37oC, 5% CO2 under zeocin selection 
for 2-3 weeks. Approximately 100 individual foci were isolated and expanded in growth 
medium under hygromycin and zeocin selection. For each clone, cells were added to 10 
cm dishes, cultured overnight, shifted to growth medium with or without the inducer 
mifepristone (625 pM) for 48 h, and lysed. Clones were screened for background 
expression of ectopic HA-eIF4E without induction and mifepristone-induced expression 
of HA-eIF4E by immunoblot. Two clones were utilized for the experiments reported 
here: 1) “non-inducible” control cells do not express ectopic eIF4E despite exhibiting 
resistance to hygromycin and zeocin, i.e. the cells contain all of the ectopic GeneSwitch 
expression system plasmids but do not exhibit exogenous gene expression upon 
induction; and 2) “4E-inducible” cells express ectopic eIF4E at a level comparable to the 
endogenous gene, yielding an approximately 2-fold overexpression. For our ectopic 
eIF4E induction studies, cells were first rendered quiescent in “defined medium” (F-12 
supplemented with 25mM Hepes, 0.1 mg/ml bovine serum albumin, 10 mg/ml holo-
transferrin, 10-8 M selenium, 3*10-6 M linoleic acid; with 40 ng/ml IGF + 5 ng/ml EGF to 
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preserve viability; all components from Sigma-Aldrich) for 22 h (99); with cultures 
continued for the indicated amount of time in defined medium +/- the inducer 
mifepristone (625pM). 
Immunoblot analysis 
Cells were lysed with RIPA lysis buffer [1% NP-40, 50 mM Tris pH 7.5, 150 mM NaCl, 1% 
sodium deoxycholate, 1% SDS (all Sigma-Aldrich)] supplemented with protease inhibitor 
(Roche) and protein quantified using a BCA protein assay kit (Pierce). Equal amounts of 
cell lysate protein per lane were subjected to SDS-PAGE and transferred onto 
nitrocellulose membranes. Antibodies directed against eIF4E (mouse monoclonal 
antibody, 1:500, BD Transduction Laboratories) and actin (rabbit polyclonal antibody, 
1:1500, Sigma-Aldrich) were used to identify these proteins. Signal was detected with 
secondary antibodies conjugated to horseradish peroxidase (Calbiochem) and 
developed with chemiluminescent ECL Western Blotting Detection Reagents (GE 
Healthcare Life Sciences). 
Cell based translational activity assay 
To quantify the global level of cap-dependent translation, a luciferase reporter system 
was utilized (74). Cells were transfected with 1 µg of pcDNA3-rLuc-polio-fLuc, and fresh 
media was added 6 h after transfection. Cells were rinsed with PBS 24 h after 
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transfection and induced to express ectopic eIF4E with mifepristone (625pM). After 24 
h, cells were lysed with passive lysis buffer (Promega) for 15 min, cell debris was 
pelleted by centrifugation and triplicate supernatant samples were assayed for 
luciferase activity in a Lumat LB 9507 luminometer (BG&G) using the Promega Dual-
Luciferase Reporter System. 
In vitro translational activity assay 
To verify that 4Ei-1 functioned as a translational repressor, a cell-free luminescence 
reporter system was utilized. A master mix was created with 1.25 µL 20x buffer and 17 
µL rabbit reticulocyte lysate from the Retic Lysate IVT kit (Life Technologies) and 1 µL l-
methionine (final concentration 50 µM) and 0.5 µL (1 µg) pcDNA3-rLuc-polio-fLuc mRNA 
reporter. The master mix was aliquoted into microcentrifuge tubes with 5.25 µL of 4Ei-1 
(over a dose range of 0 - 100 µM) and the reaction was allowed to proceed at 30°C for 
75 min. 100 µM 7-MeGTP was used as a positive inhibitory control. Five µL of each 
reaction mix was combined with 100 µL of nuclease-free water. Five µL of this mix was 
assayed for Renilla luciferase activity in a Lumat LB 9507 luminometer (BG&G) using the 
Promega Dual-Luciferase Reporter System. 
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RNA preparation 
Total cellular and ribosome-associated RNA were prepared as described previously (65). 
In order to assess ribosome recruitment to each and every mRNA transcript, cell 
homogenates were overlaid onto a 5 ml sucrose gradient, stratified by 
ultracentrifugation and fractionated into ten 0.5 ml fractions, numbered 1 (lightest, no 
ribosomes bound) to 10 (heaviest, most ribosomes bound). These ten fractions of 0.5 ml 
were collected into tubes containing 50 μl of 10% SDS. 
RNA quantification 
To assess the effect of mifepristone induction on ectopic HA-eIF4E’s overall transcript 
abundance and ribosome recruitment, total cellular RNA and fractions 3 to 10 of 
ribosome-associated RNA were individually purified using Tri-reagent (Sigma-Aldrich) 
and reverse transcribed to cDNA using the TaqMan reverse transcriptase kit (Roche). 
Fractions 1 and 2, containing translationally inactive RNA not bound to ribosomes, were 
not quantified. Quantitative PCR (Q-PCR) was performed using the Roche Light-Cycler 
1.5 with SYBR Green dye (Roche). The HA-eIF4E primer used was: 5′-
ACGTTCCAGATTACGCTGCT-3’ (forward) and 5′-AGAGTGCCCACCTGTTCTGT-3” (reverse). 
The reaction products were subjected to gel electrophoresis to confirm the presence of 
a single PCR product of the appropriate length. Data from total cellular RNA was 
normalized to a 0 h (baseline) value of 1.0. 
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HPLC-ESI-MS/MS instrumentation 
4E-inducible cells were plated at 3 million cells/10cm plate, serum starved for 24 hr, and 
then treated for 4 hrs with 500µM 4Ei-1 in the media indicated (DMEM = Dulbecco's 
Modified Eagle Medium, FBS = Fetal Bovine Serum, Serum Starved = defined media). 
Intracellular lysates were resuspended in 100uL Hepes prior to LC/MS analysis. Cell-
experienced media was also collected along with the cells and analyzed via LC/MS. Cell-
free control media was also collected which was placed in fresh 10cm dishes and also 
incubated at 37°C without cells. All samples were then analyzed as performed previously 
(75). 
Media pH test 
As 4Ei-1 is less stable at acidic pH, we analyzed the pH of cell-free and cell-experienced 
media. 3 million cells/10cm plate were played and serum deprived for 22 hrs in defined 
media and then treated with mifepristone and 250 µM verapamil or 500 µM 4Ei-1 and 
incubated for 4 hours at 37°C and 5% CO2. The pH of each media sample was 
determined using a Corning Pinnacle 530 pH meter. 
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Quantification of translational activity 
To assess genome-wide translational activity, RNA from sucrose-gradient fractions 7 to 
10, representing heavily translated mRNA containing 4 or more bound ribosomes per 
transcript, was pooled and termed polysome-associated RNA. Total cellular RNA and 
polysome-associated RNA were quantified and quality checked using both the 
NanoDropND-8000 and Caliper Labchip GX. Samples passing quality thresholds (260/280 
ratio > 1.8 and an RNA Integrity Number (RIN) of 7.1 or higher (average = 9.2, SD = 0.7)) 
were labeled using an Illumina TotalPrep-96 RNA Amplification Kit, hybridized to 
Illumina murine WG-6 v2.0 expression BeadChips and the resulting signal was captured 
with an Illumina iSCAN scanner.  The data was normalized using robust spline 
normalization and log2 transformed in R/Bioconductor. As the large number of samples 
required the data to be run across multiple chips, technical replicates were included and 
bead summary data were batch corrected as described previously (100). Probes for 
which the expression level exceeded all negative controls (detection p-value = 0.0 as 
defined by the Illumina platform) in 2/3 of total cellular RNA samples were included in 
downstream analysis. Gene expression levels were mapped from probe levels by 
selecting the highest expressing probe from each mapped gene. Using these criteria, 
7,201 genes were identified. Data integrity was verified by testing 5’ to 3’ ratios and 
scaling factors. This dataset has been deposited at the Gene Expression Omnibus (GEO). 
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Because the amount of each transcript bound to polysomes depends in part upon the 
abundance of that particular transcript in the cytoplasmic pool, in order to determine 
whether each gene is regulated specifically at the step of translation, the expression 
level of the gene in the polysomal RNA sample was corrected for the expression level of 
that gene in the corresponding total cellular RNA sample. This is often done by 
considering the ratio [polysomal mRNA] / [total cellular mRNA], termed the translational 
efficiency (TE) or translational ratio (TR). However, this assumes that an increase in total 
cellular mRNA levels is noiselessly associated with a corresponding increase in the 
polysomal mRNA level, an assumption that leads to increased false positives (101). We 
used a more robust correction, ANalysis Of Translational Activity (ANOTA), in which 
polysomal RNA is corrected by a linear fit to the total cellular RNA (102):  
Expolysomal = γtotal ∙ Extotal +γbiological variable 
where Expolysomal is the measured expression of a given gene in the polysomal mRNA, 
Extotal is the measured abundance of a given gene in the total cellular mRNA, γtotal is the 
fitted linear dependence of the polysomal expression on the total cellular expression 
and γbiological variable is the change in translation induced by the biological variable in the 
comparison. The resulting p-values were corrected using RVM adjustment (103). 
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Categorization of genes by eIF4E sensitivity 
We utilized a multi-step approach to stratify the translational activity of genes by eIF4E 
sensitivity: 
Step 1:  Identify genes differing (p < 0.05; corresponding to an FDR of 0.41) in the 
comparison of 4E-inducible cells + mifepristone with 4E-inducible cells + mifepristone + 
4Ei-1 (200 µM). 
Step 2: In order to reduce false positives, we also required a true positive to achieve p < 
0.05 in the comparison of 4E-inducible cells + mifepristone to 4E-inducible cells - 
mifepristone. Genes with significantly decreased translational activity from step 1 which 
also showed increased expression in this comparison were designated “4E 
hypersensitive genes” (111 genes), and genes with significantly increased translational 
activity from step 1 which also showed decreased expression after mifepristone 
treatment compared to no mifepristone treatment were designated “4E hyposensitive 
genes” (77 genes). 
Annotation of RNA features 
The 5’ and 3’ UTRs of the UCSC canonical isoform (104, 105) for each gene were 
annotated in R using the Bioconductor packages GenomicFeatures (106) and 
TxDb.Mmusculus.UCSC.mm9.knownGene (107). Unique microRNA targets of each gene 
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were annotated using targetScanMouse via the targetscanMouse.db package in R (108). 
Genes with AU-rich sequences were annotated using the ARED organism database 
(109). Genes with GU-rich sequences were defined by searching their canonical isoform 
for the sequence UGUUUGUUUGU (80) and the defined GU-rich repeat sequence (81). 
Gene ontology analysis 
In order to identify biological processes associated with the 4E hyposensitive and 4E 
hypersensitive genes, Fisher’s exact test was used on ontologies from the gene ontology 
consortium (110) to determine those that were over-represented in each group (FDR < 
0.1). 
Cell cycle analysis 
Cells were seeded in growth medium at 33,000 cells/35 mm well of a 6-well cluster.  
Growth medium was replaced with defined medium on day 7 for 22 h, cells were pre-
treated for 4 h with [0 – 500 µM] 4Ei-1 in defined medium and shifted to treatment 
medium (defined medium + treatment condition) for 24 h. For each sample, the 4 h 
pretreatment concentration of 4Ei-1 was identical to the 24 h treatment concentration 
for that sample. Cultured cells were rinsed with PBS, detached with trypsin, washed 
with PBS + 1% FBS to inactivate trypsin, washed in staining buffer [Hank’s balanced salt 
solution w/ magnesium chloride and calcium chloride (Life Technologies), supplemented 
  69 
with 1% FBS, 1g/L glucose, and 20 mM Hepes (pH 7.2)] and pelleted by centrifugation. 
Cells were resuspended in 1 ml staining buffer supplemented with Hoechst (40 µg/ml) 
and Pyronin Y (1 µg/ml), incubated for 45 min at 37⁰C, washed in staining buffer and 
analyzed using an LSR II flow cytometer (Becton Dickinson [BD]). The percentages of 
cells with G1 and S+G2/M DNA content was determined with FlowJo software (version 
7.5) using published protocols (111). All statistical values were generated using unpaired 
two-tailed t-tests, and all error bars indicate standard deviation. 
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Chapter 3 : eIF4E mediates G0 exit and cell cycle transit via 
a Cyclin C-independent mechanism 
Introduction 
Cell Cycle 
The regulation of cellular proliferation is critically important in physiological cell growth 
and is aberrantly usurped in almost all cancers. Proliferation can only be achieved in 
mammalian cells after DNA replication in the cell cycle, which is therefore a key 
regulatory node (Figure 3-1 from (112)). 
  71 
 
Figure 3-1 The cell cycle 
Mammalian cell proliferation occurs through a series of stages that are collectively termed the 
cell cycle. The cell cycle can be divided into four phases: DNA synthesis (S), mitotic segregation 
(M), and two intervening gap phases (G1 and G2) preceding S and M phases, respectively. 
Progression through the cell cycle requires hyperphosphorylation of the retinoblastoma (RB) 
protein and is highly regulated, particularly at the “checkpoints” from G1 phase to S phase and 
from G2 phase to M phase. These checkpoints are controlled in part by the association of the 
cyclin family of proteins with cyclin dependent kinases (cdk’s) to form an enzymatically active 
complex, and their antagonist cell cycle inhibitors (CDKIs), discussed below. This figure has been 
reprinted with kind permission from Nature Publishing Group. 
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Cyclin C is involved in G0 exit 
The regulated balance of cell proliferation and quiescence is critical for tissue 
homeostasis and organismal health. Cells in a quiescent state are outside of the cell 
cycle, and are defined as in G0 phase. During G0 phase global protein synthesis is largely 
down-regulated, but a subset of mRNAs is specifically translated to ensure cell survival 
and responsiveness to proliferative signals (113). These proteins tightly control exit from 
G0, and despite the importance of this regulatory node current knowledge is still lacking 
in this area. One of the mRNAs known to be highly expressed in G0 is cyclin C (114). 
Cyclin C mRNA levels also increase specifically only in the G0 population of quiescent 
serum pulsed cells (115). Cyclin C (CCNC) was originally found to associate with cyclin-
dependent kinase 8 (cdk8) and this complex regulated the efficiency of RNA Polymerase 
II transcription by phosphorylating its carboxy terminal domain (CTD) in the presence of 
a CTD-specific kinase (116). However, when cyclin C complexes with cdk3 instead, this 
complex stimulates retinoblastoma (Rb) phosphorylation at serine 807/811, and this 
phosphorylation is required for cells to exit G0 efficiently as it occurs prior to cyclin D1-
mediated phosphorylation of Rb (111). Acute inactivation of pRB alone is also sufficient 
for G0-arrested cells to reenter the cell cycle (117). This data indicate that RB 
phosphorylation is critical for G0 exit, but the molecular trigger and relative significance 
of cyclin C-induced phosphorylation is unclear. 
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Cyclin D1 controls the R point through phosphorylation of the 
retinoblastoma protein 
Once a mammalian cell has exited G0, a combination of intrinsic and extrinsic signals 
regulate the transition from early to late G1 phase. This transition is termed the 
restriction (R) point, and divides the G1 phase of the cell cycle into the mitogen-
dependent early G1 phase and the mitogen-independent late G1 phase (118). During 
normal physiological homeostasis and tissue regeneration, cells must be stimulated by 
mitogenic signals (i.e. soluble growth factors) to traverse the G1 phase and enter into 
the cell cycle. After the R point the cell has committed to enter the cell cycle and 
mitogenic stimuli are no longer required. 
Transit through the R point is largely controlled by cyclin D and the retinoblastoma (Rb) 
protein. When quiescent cells are exposed to growth factors, cyclin D1 abundance in the 
cytoplasm increases as it associates with one its partner kinases, cdk4 or cdk6, resulting 
in their activation (119). The activated cyclin D1-cdk complexes enter the nucleus where 
they phosphorylate Rb on residue serine-780 (120). Cyclin D1 in turn is rapidly 
phosphorylated by glycogen synthase kinase-3 beta (GSK3β) on Thr-286, triggering 
nuclear export and ubiquitin mediated degradation by the 26S proteasome (121). 
Once past the R point the mitogen-independent activation of cyclin E-cdk2 complexes 
elicit further hyperphosphorylation and inactivation of Rb and other family members 
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(122). This leads to release of E2F family members, which then regulate transcription of 
genes necessary for S-phase entry and continued cell cycle progression towards the G2 
and M phases of the cell cycle (123). 
Cyclin-dependent kinase inhibitors regulate the formation of cyclin-cdk 
complexes. 
Cdk’s are activated after binding to their respective cyclin partner, but cdk’s can be 
maintained in an inactive state after binding with cyclin-dependent kinase inhibitors 
(CDKIs). Two families of CDKIs regulate the transition through G1 phase. Members of the 
Ink4 family (p15, p16, p18, p19) are direct inhibitors of the association of the early G1 
cyclin D–cdk4 and cyclin D–cdk6 complexes , and members of the CIP/KIP family 
(p21CIP, p27KIP1, p57KIP2) are direct inhibitors of the association of the late G1 cyclin 
E–cdk2 complexes (124). Therefore high CDKI activity is effective at slowing or blocking S 
phase entry. 
eIF4E is known to translationally regulate key oncogenic proteins 
eIF4E is known to translationally regulate the abundance of: key cell cycle drivers 
including ornithine decarboxylase (38), cyclin D1 (40), fibroblast growth factor 2 (125); 
and other oncogenic proteins including matrix metallopeptidase 9 (126), the 
transcription factor c-Myc (53), and the angiogenic vascular endothelial growth factor 
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(VEGF) (43). These pleiotropic effects of eIF4E on the full range of cancer-related 
functions have made elucidating the mechanism of eIF4E-mediated transformation a 
challenge. In addition, the majority of these early studies were limited by potential 
indirect effects and counter regulation arising from long term cell culturing with 
constitutively active eIF4E (127). Dissecting the localized roles of eIF4E on individual 
transcripts has also proven difficult, as eIF4E forms nuclear bodies and regulates the 
nucleo-cytoplasmic export of key mRNAs in addition to its role in the cytoplasm to 
initiate translation (78). For example, eIF4E was shown to promote nuclear export of 
cyclin D1 mRNAs via an element in the 3'UTR but the technology of the time was unable 
to show that eIF4E selectively increases the translation of cyclin D1 (40, 128). Therefore 
the molecular mechanisms by which eIF4E impacts cell cycle function are incompletely 
defined, especially in the physiological context of quiescence and cancer genesis. Here 
we show that abrupt gain of eIF4E function in quiescent cells triggers G0 exit and cell 
cycle transit and increases ribosome recruitment to cyclins C and D1. These data 
establish an oncogenic mechanism linking increased levels of cellular eIF4E and 
proliferative autonomy in the absence of growth factors. 
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Results 
Ectopic eIF4E expression elicits G0 exit and cell cycle transit 
To elucidate the molecular mechanisms by which abrupt activation of the cap-
dependent translation initiation complex modulates cell cycle kinetics, quiescent 4E-
inducible cells were treated with or without the inducer mifepristone, thus increasing 
eIF4E protein levels from those commonly observed in quiescent cells to levels 
commonly seen in cancer (88). We then determined cell cycle status by flow cytometric 
quantification of DNA and RNA content. eIF4E induction elicited a pronounced decrease 
in the percentage of G0 cells, from a baseline of 24% G0 to 7% at 26 hours (Figure 3-2A), 
thus signifying G0 exit. eIF4E induction increased cell cycle transit (hereafter defined as 
cell cycle progression through the R point and into S and G2 phases) after G0 exit, as 
evidenced by a 4-fold increase in the percentage of cells in S and G2 phase when 
compared with this baseline (Figure 3-2B). Although this increase was consistent, it was 
also modest, as no more than 6% of mifepristone-induced cells were observed in S or G2 
phase at any time point. In accord with prior reports, we observed a small, but 
persistent proportion of cells in S or G2 phase, even at high density after serum 
deprivation (129). To exclude a clone-specific effect, we examined 3 additional clones 
which expressed eIF4E after mifepristone induction and observed similar results (data 
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not shown). These data establish a direct relationship between eIF4E abundance, 
translational activation, G0 exit and cell cycle transit from G1 phase through M phase. 
 
Figure 3-2 Ectopic eIF4E expression elicits G0 exit and cell cycle transit. 
(A) Cell cycle timecourse of quiescent 4E-inducible cells treated as indicated. DNA and RNA 
content was quantified by flow cytometry using Hoechst 33258 and Pyronin Y, respectively. 
Shown is the percent of cells in G0 normalized to the 0 hr timepoint, which showed 23.7% of 
cells in G0. The G0 population was defined as cells with 2n DNA content and RNA content less 
than cells with 4n DNA content. Shown is a representative replicate of 3 independent 
experiments, with error bars indicating ±SD of triplicate samples from a single experiment. 
Serum deprived cells were used as an untreated negative control and 1 nM PDGF (platelet 
derived growth factor) as a positive control. (B) Data obtained concurrent to panel A data. 
Shown is the percent of cells in S+G2/M as a function of time. 
eIF4E-mediated cyclin C translational activation is not necessary 
for G0 exit and cell cycle transit 
Cyclin C (CCNC), in partner with kinases including cdk2 and cdk3, can mediate G0 exit 
(111, 130). We therefore monitored ribosome recruitment to the cyclin C transcript in 
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response to rapid eIF4E induction. The predominant effect on cyclin C mRNA was an 
increase in ribosome loading as seen by a shift from lighter to heavier polysomes (Figure 
3-3A). To differentiate this shift from the genome-wide translational activation elicited 
by ectopic eIF4E expression, cytochrome C served as an invariant control (Figure 3-3B) 
(65). As expected, there was no significant difference between the total cellular mRNA 
abundance of cyclin C and cytochrome C, and HA-eIF4E continued increasing in the 3 
hour time period probed (Figure 3-3C). Therefore cyclin C is translationally activated by 
eIF4E induction. 
Knockdown of cyclin C has previously been shown to delay G0 exit and S phase entry 
(111). To examine whether cyclin C was necessary for eIF4E-mediated G0 exit and cell 
cycle transit, we transduced 4E-inducible cells with a GFP expressing shRNA construct 
targeting cyclin C, sorted on GFP expression (Figure 3-3D), and reduced cyclin C mRNA 
by 54% when compared to the non-silencing (NS) control (Figure 3-3E). Despite this 
reduction, there was no significant change in eIF4E-mediated G0 exit (Figure 3-3F), 
indicating that cyclin C is not necessary for eIF4E-mediated G0 exit. Although there was a 
trend towards non-silencing shRNA delaying G0 exit (p=0.054) at 12 hrs, cyclin C 
knockdown was unable to ablate or delay eIF4E-mediated G0 exit. As expected, serum 
deprived cells showed a slight increase in the percentage of G0 cells over time and PDGF 
elicited a significant decrease in the percentage of G0 cells over time (data not shown). 
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Cyclin C knockdown also had no significant effect on eIF4E-mediated cell cycle transit 
(Figure 3-3G). 
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Figure 3-3 eIF4E-mediated cyclin C translational activation is not necessary for G0 exit 
and cell cycle transit 
(A) mRNA from mifepristone treated 4E-inducible cells was stratified on a sucrose gradient and 
fractionated into 8 increasingly translationally active fractions, numbered 3 (lightest, fewest 
ribosomes bound) to 10 (heaviest, most ribosomes bound). mRNA was quantified by Q-PCR as a 
function of time after induction. Shown is the relative polysomal transcript abundance of cyclin 
C mRNA. Each data point is expressed as the percent of that fraction divided by the sum of 
fractions 3-10 for that timepoint (0, 1, 2 or 3 hrs). (B) Same for cytochrome C mRNA. (C) Time 
course of total cellular mRNA expression of HA-eIF4E, cyclin C, and cytochrome C. Quiescent 4E-
inducible cells were incubated with mifepristone for up to 3 h, RNA purified and subjected to Q-
PCR analysis. Data was normalized to a 0 h (baseline) value of 1.0.  (D-G) 4E-inducible cells were 
transduced with a lentiviral shRNA construct expressing GFP which targeted either cyclin C 
(CCNC) or was non-silencing (NS). Cells were flow sorted for GFP expression (D), and expanded 
GFP+ cells subjected to Q-PCR analysis of cyclin C. Error bars indicate duplicate Q-PCR samples in 
a single experiment (E). Unsorted cells were also quiesced, mifepristone treated for the 
indicated time period, and analyzed for cell cycle status. Shown is the percentage of GFP+ cells 
in G0 normalized to the 0 hr timepoint (F) and GFP+ cells in S+G2 (G) as a function of time. DNA 
and RNA content was quantified as performed previously. Shown is a representative replicate of 
3 independent experiments. Error bars indicate quadruplicate samples within 1 individual 
experiment. The percentage of cells in G0 is normalized to the GFP+ 0 hr timepoint, which 
showed 21.8% of cells in the GFP+ population. 
Increased cyclin D1 is required but not sufficient for eIF4E-
mediated cell cycle transit 
We next examined the effect of eIF4E induction on negative and positive regulators of 
the G1/S cell cycle checkpoint. To calibrate the response range, we utilized PDGF as a 
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single trophic agent and serum as a pleiotropic stimulus. Cyclin D1 was the only protein 
whose expression levels changed among the cell cycle regulators surveyed, increasing 8-
fold in abundance (Figure 3-4). 
 
Figure 3-4 Abundance of G1/S Checkpoint Regulators after eIF4E Induction 
Quiescent cells were cultured with or without 625pM mifepristone for 24h, lysed and subjected 
to immunoblot analysis for a panel of G1/S checkpoint regulators. 10% fetal bovine serum (FBS) 
and 50pM PDGF served as positive controls, and actin served as a loading control. 
Prior studies indicate that when established NIH3T3 cell lines constitutively over express 
eIF4E, cyclin D1 abundance is increased through eIF4E facilitated nuclear export of the 
cyclin D1 mRNA, rather than through increased recruitment of ribosomes (131, 132). To 
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examine the mechanisms when eIF4E activity is abruptly increased, we monitored cyclin 
D1 mRNA abundance and its association with ribosomes. The total cellular mRNA 
abundance of cyclin D1 did not change after eIF4E induction (Figure 3-5A). Instead we 
observed a rapid translational activation of the cyclin D1 transcript (Figure 3-5B). This 
increased ribosome recruitment, coupled with increased nuclear export, can promote 
an increased accumulation of the cyclin D1 protein. 
Introduction of cyclin D1 into quiescent primary hepatocytes is sufficient to trigger cell 
cycle transit (133, 134). Therefore, it was in principle possible that eIF4E mediated cell 
cycle transit might be mediated solely by the observed increase in cyclin D1. To address 
this issue, we utilized 3 different shRNA’s, each targeting a different region of the cyclin 
D1 transcript, to achieve a knockdown of cyclin D1 ranging from 64%-85% (Figure 3-5C). 
There was a concomitant abrogation of eIF4E-mediated cell cycle transit in each case, 
including modest but reproducible suppression of basal S phase entry in the uninduced 
state (Figure 3-5D).  Thus, eIF4E mediated cell cycle transit cannot be rescued by the 
pleiotropic effects of eIF4E on global translation; and depends upon the ability of eIF4E 
to increase cyclin D1. 
To examine whether cyclin D1 alone was sufficient to trigger G0 exit and cell cycle 
transit, we utilized an adenoviral expression system to ectopically express cyclin D1 
(134). Quiescent cells were infected with adenovirus expressing cyclin D1 at a 
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multiplicity of infection (MOI) of 40 or 175; or induced with mifepristone. Adenovirus 
expressing beta-galactosidase at a MOI of 40 served as a negative control and 1nM 
PDGF served as a positive cell cycle control. We achieved comparable levels of cyclin D1 
expression between mifepristone induced cells and cyclin D1 adenovirus infected cells 
at a MOI of 40 (Figure 3-5E). Nonetheless, ectopic cyclin D1 expression was not 
sufficient to increase the percentage of cells in S and G2 phase either by itself or in 
combination with eIF4E induction (Figure 3-5F). A slight statistically significant 
difference (p<0.003) was seen with ectopic cyclin D1 expression in combination with 
PDGF compared with PDGF alone (52.88% S+G2/M vs 50.22%). However , the 
combination of eIF4E induction and PDGF yielded a more striking increase in cell cycle 
transit (56.15% S+G2/M vs 50.22%, p<0.0001) when compared to PDGF alone, and this 
increase (5.93%) was comparable to the increase in eIF4E induction alone (5.78%), when 
compared to control. A similar result was obtained for G0 exit, as ectopic cyclin D1 was 
unable to alter the percentage of cells in G0 either by itself, when paired with 
mifepristone, or when paired with PDGF (Figure 3-5G). Therefore, cyclin D1 is not 
sufficient to replace the effect of eIF4E on cell cycle transit and/or G0 exit. 
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Figure 3-5 Increased cyclin D1 is required but not sufficient for eIF4E-mediated cell 
cycle transit 
(A) Time course of cytoplasmic cyclin D1 mRNA expression. Quiescent 4E-inducible cells were 
incubated with mifepristone (625pM) for up to 3 h, RNA purified and subjected to Q-PCR 
analysis. Data was normalized to a 0 h (baseline) value of 1.0. (B) mRNA from mifepristone 
treated 4E-inducible cells was stratified on a sucrose gradient and quantified by Q-PCR as a 
function of time after induction. Shown is the relative polysomal transcript abundance of cyclin 
D1 mRNA. (C) 4E-inducible cells were transduced with one of three distinct lentiviral shRNA 
constructs, each targeting a different region of the cyclin D1 mRNA (designated shRNA 33, 48 or 
83). Empty lentiviral vector is used as a control. Quiescent transduced cells were then incubated 
with or without mifepristone for 24h, lysed and subjected to immunoblot analysis for 
cytoplasmic cyclin D1. Actin is shown as a loading control. Numbers are relative optical density 
(OD). (D) 4E-inducible cells expressing one of the 3 cyclin D1 shRNA constructs or empty vector 
(control) were rendered quiescent, incubated for 24h with or without mifepristone, fixed, 
stained with propidium iodide, and DNA content was quantified by flow cytometry. Shown is the 
percent of cells in S+G2/M. (E) 4E-inducible cells were transduced with one of two distinct 
adenoviruses: control virus expressing beta-galactosidase shRNA at a multiplicity of infection 
(MOI) of 40, or cyclin D1 shRNA at an MOI of 40 (+) or 175 (++). Quiescent cells were cultured for 
24h as indicated with or without mifepristone (MIF) and 1nM PDGF, lysed and subjected to 
immunoblot analysis for cyclin D1. Actin is shown as a loading control. Numbers are relative 
optical density (OD). (F) Concurrent with panel E, treated cells were fixed, stained with 
propidium iodide, and DNA content was quantified by flow cytometry. Shown is the percent of 
cells in S+G2/M. Shown is a representative replicate of 2 independent experiments, with error 
bars ±SD of triplicate samples from a single experiment. *** = p <0.001 versus PDGF alone. ** = 
p <0.01 versus PDGF alone. (G) Quiescent 4E-inducible cells were treated for 26h as indicated. 
DNA and RNA content was quantified by flow cytometry using Hoechst 33258 and Pyronin Y, 
respectively. Shown is the percent of cells in G0. Shown is a representative replicate of 3 
independent experiments, with error bars indicating ±SD of triplicate or quadruplicate samples 
from a single experiment. 
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eIF4E-mediated cell cycle transit follows the canonical growth 
factor pathway 
To determine if eIF4E-mediated cell cycle transit followed the canonical growth factor 
initiated pathway, we traced the fate of cyclin D1 and its partner kinase cdk4 after eIF4E 
induction. Within 1h of induction, the abundance of ectopic eIF4E and cyclin D1 in the 
cytoplasm increased sharply, with a concomitant decrease in cdk4 that was even more 
pronounced at 2h (Figure 3-6A). Within this time frame, we found cyclin D1 associated 
with cdk4 (Figure 3-6B), and by 8h of induction we observed a 2-fold increase in Rb 
phosphorylation (Figure 3-6C). These data indicate that eIF4E enables cells to efficiently 
exit G0 and initiate cell cycle transit by facilitating transit of the Rb-governed restriction 
point at the G1/S phase boundary. 
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Figure 3-6 eIF4E-mediated cell cycle transit follows the canonical growth factor 
pathway. 
Quiescent 4E-inducible cells were incubated with or without mifepristone for the indicated time 
interval, lysed, and separated into cytoplasmic or nuclear subcellular fractions. (A) Immunoblot 
analysis for cytoplasmic cdk4, cyclin D1, and eIF4E.  Actin is shown as a loading control. Shown is 
a representative example of triplicate independent replicates. Numbers are relative optical 
density (OD). (B) Nuclear lysates were immunoprecipitated with anti-cyclin D1 antibody. Shown 
is a representative immunoblot for cdk4 and cyclin D1 of duplicate independent replicates. (C) 
Nuclear lysates were subjected to immunoblot analysis for Ser 780 phosphorylated Rb. Nuclear 
lamin is used as a loading control. Shown is a representative example of triplicate independent 
replicates. 
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Discussion 
The eukaryotic translation initiation factor eIF4E exhibits an activity level above the 
physiological range in many human malignancies and serves as an indicator for poor 
prognosis (135). Previous investigations of eIF4E overexpression have focused on 
modeling the effects of high eIF4E activity as seen in established human malignancies by 
utilizing constitutive overexpression of eIF4E. However, data regarding the immediate 
molecular effects of eIF4E activation in the context of cancer genesis is lacking, even 
though eIF4E is thought to be an early event on the causal path to neoplastic 
transformation (31, 136-138). This gap in knowledge leaves uncertain whether 
disruption of translational control rapidly enables a key property of cancer, autonomous 
proliferation, or if this is an indirect effect generated from other accumulated mutations 
as seen in established cancers. Therefore, parsing eIF4E’s contribution to promoting 
autonomous proliferation from other oncogenic alterations would not only provide 
insight on how deregulation of translation is essential for cancer initiation, but also for 
development of future targeted therapeutics.  
To test whether abruptly increasing eIF4E abundance could confer cells autonomous 
proliferation, one of the hallmarks of cancer, we utilized an established model cell line in 
eIF4E research, NIH 3T3 cells, and introduced a mifepristone inducible eIF4E construct, 
thus allowing quantification of G0 exit and cell cycle transit after increasing eIF4E 
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abundance to levels commonly found in early-stage human malignancies. Here we show 
that abrupt gain of eIF4E function in quiescent cells first triggers G0 exit and then cell 
cycle transit by increasing ribosome recruitment to cyclins C and D1. Whereas cyclin C is 
not necessary for this effect; cyclin D1 is indispensable, although not sufficient. It is also 
apparent that eIF4Es primary cell cycle effect is pushing cells out of G0, but the absence 
of complementary cell cycle transit indicates that a majority of these pushed cells are 
blocked from entering S phase and progressing through the cell cycle, thus limiting 
eIF4Es proliferative effect but providing a fertile ground for the cumulative effects of 
additional mutations. This adds additional mechanisms for eIF4Es potent role as an 
oncogene and function in cancer genesis while illustrating eIF4Es pleiotropic effects on 
human malignancy. 
The relative importance of cyclin C on G0 exit and cell cycle progression is still a matter 
of debate. Based on prior data, we expected cyclin C knockdown to delay G0 exit and S-
phase entry (111). However, although we only achieved a 54% knockdown of cyclin C, 
quiescent cells with severely decreased levels of cyclin C have been shown to still 
respond to growth signal induced proliferation by activating other major signaling 
pathways such as pAKT, pp42/44, and pp70 S6K (130). This may account for the 
retention of eIF4E-mediated G0 exit and cell cycle transit we observed after cyclin C 
knockdown as the pleiotropic effects of eIF4E on cell growth-related factors (35) may be 
able to compensate for the loss of cyclin C. In addition, we believe the apparent 
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difference in the 12 hour G0 timepoint (p=0.054) is not likely due to cyclin C knockdown, 
as the GFP- control cells (not expressing the shRNA construct) exhibited a similar 
difference to that observed in the GFP+ cells. Another possibility is that the enhanced 
eIF4E-mediated translation of cyclin C is able to overcome the relatively small 54% 
mRNA knockdown of cyclin C. Additional experimentation will be necessary to resolve 
the role of cyclin C in eIF4E-mediated G0 exit. 
Unfortunately the molecular mechanisms of G0 exit have not been well defined, and 
current data suggests that there are multiple mechanisms available to the cell to exit G0 
(111, 139-145), compared to a single method of transiting the R point. This correlates 
with data indicating that colon adenocarcinomas overexpress multiple cyclins, and that 
cyclin C was the most commonly overexpressed cyclin and independently associated 
with an unfavorable prognosis (146). Taken together with our data, this indicates that 
although cyclin C is an important factor for G0 exit and tumor maintenance, Cyclin C 
likely works in concert with multiple other factors and pathways which will need to be 
thoroughly analyzed using gain and loss of function studies. Unfortunately my attempts 
to define a panel (CDC6, Ki-67, p130, pRB (S807), CCNC) of protein and/or mRNA 
markers to preciously delineate G0 from early G1 were not successful due to inconsistent 
immunohistochemistry staining of G0/G1/S/G2 sorted cells, and this remains an 
important research topic. 
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The importance of cyclin D1 expression in eIF4E-mediated cell cycle transit becomes 
more apparent after elaborating on the roles of p27 and cyclin E. In quiescent NIH 3T3 
cells expressing ectopic cyclin D1, cyclin D1 forms an inactive complex with CDK4 due to 
simultaneous association with p27; and knockdown of p27 was required for S-phase 
entry (139). This may explain our observation that ectopically expressed cyclin D1 did 
not elicit G0 exit or cell cycle transit by itself or with mifepristone, as mifepristone 
treatment had no effect on p27 levels. However, cyclin D1 overexpression did increase 
PDGF-mediated cell cycle transit as PDGF treatment alone decreased p27 levels by 
~50%. Our data also indicate that although eIF4E-mediated cell cycle transit follows the 
canonical growth pathway via Rb phosphorylation; it is p27 independent; as ectopic 
eIF4E expression does not alter p27 protein levels, although eIF4E may affect p27 
function rather than protein level. Further experimentation is needed to determine if 
knockdown of p27 increases eIF4E-mediated cell cycle transit as the eIF4E-mediated 
increase in translationally activated cyclin D1 should be more effective at eliciting cell 
cycle transit without p27 present. If this increase occurs it will be another example of 
the “fertile ground” eIF4E overexpression generates, by allowing an additive effect to 
the eIF4E-mediated increase in cell cycle transit, as was seen in induced cells further 
activated with PDGF. Further emphasizing the importance of cyclin D1 overexpression 
mediated by eIF4E, we did not detect any modulation in cyclin E activity after eIF4E 
induction. Increased cyclin E expression renders the cyclin D-cdk4 complex dispensable 
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for Rb activation and S phase entry (147). Therefore increased eIF4E activity increases 
cell cycle transit via translational activation of cyclin D1 without directly affecting p27 
and cyclin E. 
Our study provides novel insights into eIF4Es role as an oncogene. Enforced over 
expression of eIF4E translationally activates cyclins C and D1, stimulates G0 exit and cell 
cycle transit, and thus is capable of bypassing key regulatory steps of the canonical 
growth factor pathway. However, an unidentified regulatory mechanism prevents the 
majority of cells which have exited G0 from entering S phase, and the eventual fate of 
these cells is unknown. These cells are primed to respond to further oncogenic stimuli, 
thus allowing the cells to progress further towards a fully oncogenic phenotype. These 
observations establish eIF4Es potent pleotropic oncogenicity and further emphasize 
cap-dependent translational control as a crucial target for cancer therapy. Along those 
lines, second generation antisense oligonucleotides targeting eIF4E are currently 
undergoing clinical studies (54, 148). 
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Materials & Methods 
Cell culture for inducible eIF4E system 
Inducible eIF4E cells were generated as previously described. All experiments were 
performed with “4E-inducible” cells which express ectopic eIF4E at a level comparable 
to the endogenous gene, yielding an approximately 2-fold overexpression. 4E-inducible 
cells were maintained at 37oC, 5% CO2 in growth medium [Dulbecco's modified Eagle's 
medium high-glucose (DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine 
serum (FBS, Sigma-Aldrich), 25mM Hepes, 100 units/ml penicillin, 100 units/ml 
streptomycin and 125 ng/ml amphotericin (Life Techologies)]. For our ectopic eIF4E 
induction studies, cells were first rendered quiescent in “defined medium” (F-12 
supplemented with 25mM Hepes, 0.1 mg/ml bovine serum albumin, 10 mg/ml holo-
transferrin, 10-8 M selenium, 3*10-6 M linoleic acid; with 40 ng/ml IGF + 5 ng/ml EGF to 
preserve viability; all components from Sigma-Aldrich) for 22 h (99); with cultures 
continued for the indicated amount of time in defined medium +/- the inducer 
mifepristone (625pM). 
Cell cycle analysis 
Cells were seeded in growth medium at 33,000 cells/35 mm well of a 6-well cluster.  
Growth medium was replaced with defined medium on day 7 for 22 h, shifted to 
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treatment medium (defined medium + treatment condition) for the indicated time 
period. Cultured cells were rinsed with PBS, detached with trypsin, washed with PBS + 
1% FBS to inactivate trypsin, washed in staining buffer [Hank’s balanced salt solution w/ 
magnesium chloride and calcium chloride (Life Technologies), supplemented with 1% 
FBS, 1g/L glucose, and 20 mM Hepes (pH 7.2)] and pelleted by centrifugation. Cells were 
resuspended in 1 ml staining buffer supplemented with Hoechst (40 µg/ml) and Pyronin 
Y (1 µg/ml), incubated for 45 min at 37⁰C, washed in staining buffer and analyzed using 
an LSR II flow cytometer (Becton Dickinson [BD]). The percentages of cells with G0, G1, 
and S+G2/M DNA content was determined with FlowJo software (version 7.5) using 
published protocols (111). All statistical values were generated using unpaired two-
tailed t-tests, and all error bars indicate standard deviation. 
Alternatively, for the cyclin D1 knockdown experiments cultured cells were detached 
with trypsin, washed with PBS, fixed with ice-cold 70% ethanol, and resuspended in 
propidium iodide (PI) staining mixture as previously described (28, 74) and analyzed 
using a FACSCalibur flow cytometer (Becton Dickinson). The percentage of cells with G1, 
S, and G2+M DNA content was determined using the FlowJo (version 7.5) program. 
RNA preparation and quantification 
Total cellular and ribosome-associated RNA were prepared as described previously (65). 
In order to assess ribosome recruitment mRNA transcripts, cell homogenates were 
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overlaid onto a 5 ml sucrose gradient, stratified by ultracentrifugation and fractionated 
into ten 0.5 ml fractions, numbered 1 (lightest, no ribosomes bound) to 10 (heaviest, 
most ribosomes bound). These ten fractions of 0.5 ml were collected into tubes 
containing 50 μl of 10% SDS. 
To assess the effect of mifepristone induction on ectopic HA-eIF4E’s overall transcript 
abundance and ribosome recruitment, total cellular RNA and fractions 3 to 10 of 
ribosome-associated RNA were individually purified using Tri-reagent (Sigma-Aldrich) 
and reverse transcribed to cDNA using the TaqMan reverse transcriptase kit (Roche). 
Fractions 1 and 2, containing translationally inactive RNA not bound to ribosomes, were 
not quantified. Quantitative PCR (Q-PCR) was performed using the Roche Light-Cycler 
1.5 with SYBR Green dye (Roche). The primers used were cyclin D1: 5′-
GCGTACCCTGACACCAATCT-3’ (forward) and 5′-ATCTCCTTCTGCACGCACTT-3’ (reverse), 
cyclin C: 5’- TCTCTGTCTGCTGTACCCTCCGTT-3’ (forward) and 5’- 
TGGAGGTGGTTTTGGTTTCGGCAT-3’ (reverse), cytochrome C: 5’-
CATCCTGGACCTCCACCTC-3’ (forward) and 5’-ACCTGGTGGGAGTGTGCTAC-3’ (reverse) 
and HA-eIF4E: 5′-ACGTTCCAGATTACGCTGCT-3’ (forward) and 5′-
AGAGTGCCCACCTGTTCTGT-3” (reverse). The reaction products were subjected to gel 
electrophoresis to confirm the presence of a single PCR product of the appropriate 
length. Data from total cellular RNA was normalized to a 0 h (baseline) value of 1.0. 
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shRNA Viral Transduction 
Lentiviral constructs (Open Biosystems) expressing small hairpin RNA against mouse 
cyclin D1 (–NM_007631) and mouse cyclin C (-NM_001122982, NM_016746) were 
generated from TRC clones for cyclin D1 and a V2LMM clone for cyclin C. The target 
sequences are:  
Clone TRCN0000055233 – 5’-TCTAAGATGAAGGAGACCATT-3’ 
Clone TRCN0000026883 – 5’-CCACGATTTCATCGAACACTT-3’ 
Clone TRCN0000026948 – 5’-CCACAGATGTGAAGTTCATTT-3’ 
Clone V2LMM_52206 – 5’-CTTACAGGATGAATCATAT-3’ 
Viral production and transduction was performed as follows.  Each shRNA construct was 
transfected along with viral helper plasmids (pMDG & pCMVΔ8.91) into HEK 293 cells 
using the Fugene6 (Roche) transfection reagent at 1:3 DNA to Fugene6 ratio (w:v).  After 
48 hours, media containing the virus was collected and filtered through a 0.45 μm filter, 
mixed (1:1 v/v for cyclin D1 and 1:5 v/v for cyclin C) with fresh growth medium 
containing 8 μg/ml polybrene (Sigma-Aldrich) and 4E-inducible cells maintained in 6-well 
dishes which were centrifuged at 2000 rpm for 1 hour. After a 48-66 hour 37°C 
incubation, the media was replaced with defined media and cultures continued for 24 
hours. The media was then replaced with either defined media, induced with 
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mifepristone, or treated with 1µM PGDF for a treatment period of 0-24 hours. Cells 
were either processed for flow cytometry analysis, or collected for cyclin D1 
immunoblot analysis, or sorted for GFP expression using a FACSAria cell sorter (BD). GFP 
expressing cells were sorted into negative or greatly positive populations as indicated. 
Each population was expanded for 4 days, and lysates were collected for qPCR analysis 
of cyclin C. 
Immunoblot analysis 
Cells were lysed with NP-40 lysis buffer [1% NP-40, 50 mM Tris pH 7.5, 150 mM NaCl (all 
Sigma-Aldrich)] supplemented with protease inhibitor (Roche) and protein quantified 
using a BCA protein assay kit (Pierce). Equal amounts of cell lysate protein per lane were 
subjected to SDS-PAGE and transferred onto nitrocellulose membranes. Antibodies 
directed against eIF4E (mouse monoclonal antibody, 1:500, BD Transduction 
Laboratories), actin (rabbit polyclonal antibody, 1:1500, Sigma-Aldrich), cyclin E (mouse 
monoclonal antibody, 1:500, Santa Cruz Biotechnology), cyclin D1 (mouse polyclonal 
antibody, 1:500, BD Pharmingen), p27 (mouse polyclonal antibody, 1:2500, BD 
Pharmingen), p16 (mouse polyclonal antibody, 1:1000, BD Pharmingen), Rb (mouse 
polyclonal antibody, 1:1000, BD Pharmingen), Phosphorylated Rb (Ser 780, rabbit 
polyclonal antibody 1:1000, Cell Signaling), and cdk 4 (mouse polyclonal antibody 
1:1000, Cell Signaling) were used to identify these proteins. Lamin (mouse polyclonal 
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antibody 1:1000, Cell Signaling) served to identify the nuclear fraction after sub-cellular 
fractionation and actin (mouse polyclonal antibody, 1:500, Sigma) served as a loading 
control. Signal was detected with secondary antibodies conjugated to horseradish 
peroxidase (Calbiochem) and developed with chemiluminescent ECL Western Blotting 
Detection Reagents (GE Healthcare Life Sciences). 
Preparation of recombinant adenovirus 
Cyclin D1 and β-gal adenovirus were produced as described previously (134). 
Sub-cellular fractionation 
Protein analysis of cytoplasmic and nuclear compartments was conducted as previously 
described (40).  Following subcellular fractionation, lysates were analyzed for eIF4E 
(ectopic & endogenous), cyclin D1, cdk4, and actin by immunoblot. Subcellular 
fractionation for Rb was conducted with the NER-PER® Nuclear and Cytoplasmic Kit 
(Thermo Scientific) as described in the product’s protocol. Nuclear fractions were 
analyzed by immunoblot for phosphorylated Rb (ser 780) and nuclear Lamin. 
Immunoprecipitation 
We followed established procedures to conduct a cyclin D1 pull-down assay (149, 150). 
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Chapter 4 : THESIS CONCLUSION 
These are the first studies to systematically examine translation genome-wide across 
the physiological range of eIF4E activity. We have shown that although increasing eIF4E 
activity translationally activates cyclin C and D1, neither of these activations are 
sufficient to fully explain eIF4Es proliferative effect. The genome-wide data further 
emphasizes this point, as eIF4E selectively and rapidly activates many cell cycle and 
proliferation-related genes. Although eIF4E pushed quiescent cells out of G0, most were 
blocked from synthesizing DNA and completing a cell cycle. Coupled with eIF4Es ability 
to inhibit apoptosis and encourage survival, this provides these translationally 
deregulated cells fertile ground for an erroneous response to mitogenic stimulation and 
the accumulation of DNA-damage induced mutations generated by a partial transit of 
the cell cycle. The elucidation of the molecular mechanism of this block and the process 
utilized by pre-malignant cells to overcome it could greatly improve cancer prevention 
and detection. Our successful characterization of the 3’UTR and 5’UTR structural 
features of 4E-hypersensitive genes allows us to propose potential mechanisms for the 
eIF4E-mediated 3’UTR mRNA regulation, cell cycle progression, and oncogenic capability 
discussed previously in this dissertation. 
Therefore the next step is targeted treatment of the translational apparatus in the 
treatment of many cancers and fibrotic diseases. This thesis outlines a potential 
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approach for dissecting the translational apparatus in various malignancies with 
deregulated translational control. The recent development of a repertoire of small 
molecule inhibitors targeting specific functions of eIF4E, mTOR, eIF4A, eIF4G, Mnks, and 
other key translational proteins allows a thorough structural and functional 
characterization of the selection and regulation of specific mRNAs by the translational 
apparatus. These and other studies provide the foundation for future studies in which 
precisely targeted reclamation of physiological translational control is utilized as cancer 
therapy. 
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